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SUMMARY 
 Epidemiological studies have demonstrated that consumption of food rich 
in fruits and vegetables results in low incidence of cancers.  Although it is not 
clear which components in fruits and vegetables are responsible for this 
preventive anti-cancer property, evidence point towards the presence of fibres, 
vitamins, minerals, polyphenols, terpences, alkaloids and phenolics in fruits and 
vegetables as the contributing factors.   
 Flavonoids comprise the most common group of plant polyphenols and 
provide much of the flavour and colour to fruits and vegetables.  When consumed 
in our daily life, flavonoids are able to provide beneficial effects like anti-
oxidative, anti-viral, anti-tumour and anti-inflammatory activities.  
 The molecular mechanism underlying the anti-tumour activity of 
flavonoids has been extensively studied.  However their effects on 
nasopharyngeal carcinoma (NPC) cells are relatively less studied.   Therefore, in 
this study, we systematically investigated the anti-tumour property of two 
common flavonoids namely luteolin and quercetin on two NPC cell lines, CNE2 
and HK1 including (i) the effects of quercetin on cell growth inhibition and 
apoptosis and (ii) the effects of luteolin on cell cycle arrest and (iii) the 
sensitisation effect of luteolin and quercetin on apoptosis induced by cancer 
chemotherapeutics. 
 We first identified the mechanism underlying quercetin-mediated cell 
cycle arrest in NPC cells.  Quercetin was able to inhibit the transcription factor 
E2F-1 by keeping pRb in the hypophosphorylated form.    E2F-1 is a transcription 
factor controlling the expression of cyclin E, the cyclin requires for S phase 
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progression.  In addition, quercetin was able to induce apoptosis in CNE2 and 
HK1 by up-regulating the expression of Bad and Bax. 
 Next we investigated the molecular mechanisms underlying the cell cycle 
arrest induced by luteolin in CNE2 and HK1 cells and our study demonstrated the 
following:  (i)  Luteolin inhibited cell cycle progression at G1 phase and 
prevented entry into S phase in a dose- and time-dependent manner;  (ii) Luteolin 
treatment led to down-regulation of cyclin D1 via enhanced protein 
phosphorylation and proteasomal degradation, leading to reduced CDK4/6 
activity and suppression of retinoblastoma protein (Rb) phosphorylation, and 
subsequently inhibition of the transcription factor E2F-1. (iii) Lastly, luteolin was 
capable of suppressing Akt phosphorylation and activation, resulting in de-
phosphorylation and activation of glycogen synthase kinase-3beta (GSK-3β).  
Activated GSK-3β then targeted cyclin D1, causing phosphorylation of cyclin D1 
at Thr
286
 and subsequent proteasomal degradation. Since Akt is often over-
activated in many human cancers including NPC, it is thus believed that data from 
this study support the potential application of luteolin as a chemotherapeutic or 
chemopreventive agent in human cancer.  
 In the third part of this study, we examined the sensitisation effect of 
quercetin and luteolin, both used at sub-cytotoxic concentrations on apoptosis 
induced by vincristine, a commonly used cancer therapeutic agents, in both CNE2 
and HK1 cells.  Data from this part of our study thus provide experimental 
evidence for potential application of combination therapy using these two 
flavonoids. 
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 In conclusion, the present study provides evidence to support the potential 
application of flavonoids like luteolin and quercetin as chemopreventive or 
chemotherapeutic agents. 
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 Cancer has one of the highest mortality rates worldwide despite great 
effort by research and industry in this field.  It causes up to 7 million deaths 
worldwide based on  a 2007 global study and is also the second leading global 
killer in the world, accounting for 12.5% of all deaths (Garcia et al., 2007).  
Although there are significant advances in cancer treatment over the past decades, 
current therapeutics have not changed and the decrease in mortality relies mostly 
on early detection and prevention rather than the consequence of effective 
therapeutics (Etzioni et al., 2003; Jemal et al., 2010).  
 An important aspect of cancer control and management resides in the 
epidemiology of the disease.  Epidemiological studies have linked certain types of 
cancer among certain groups of people (Haenszel and Kurihara, 1968; Kolonel et 
al., 2004; Ziegler et al., 1993) and populations that consume food rich in fruits and 
vegetables have a lower incident rate of cancer development (Block et al., 1992; 
Reddy et al., 2003; Willett, 2000).  Fruits and vegetables contain high fibre 
content, vitamins, minerals as well as components like polyphenols, terpenes, 
alkaloids and phenolics.  The last group of components are the phytochemicals 
and flavonoids and these agents have been found to suppress inflammatory 
processes that can lead to transformation, hyperproliferation and the initiation of 
tumourigenesis.  
 Tumourigenesis is a multi-step process that can be triggered by many 
factors amongst them carcinogens including environmental antigens, 
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inflammatory agents and tumour promoters (Mathers et al., 2010).  These 
carcinogens are known to activate intracellular pathways linked to cell division 
and growth; angiogenesis and anti-apoptosis.  Dietary agents like phytochemicals 
and flavonoids are known to act on some of the intracellular pathways which not 
only prevent but can also be used as therapy of cancers (Aggarwal and Shishodia, 
2006). 
  
1.1.2 Cancer initiation and progression 
 Over the last decades, many key genes responsible for tumourigenesis 
have been identified.  In addition,  mutations to these genes have also been 
mapped and the pathway through which they act characterised.  Cancer initiation 
and progression is regarded as a multi-step process involving progressive genetic 
alterations that leads to the transformation of normal cells into highly malignant 
precursors (Bertram, 2000). 
 Genetic alterations resulting in tumourigenesis are seen in three types of 
genes; oncogenes, tumour-suppressor genes and stability genes (Ponder, 2001; 
Stratton et al., 2009; Volgelstein and Kinzler, 2004). Unlike certain diseases like 
muscular dystrophy whose manifestation is due to a mutation to one gene, cancer 
development is caused by defects in several genes.  Mammalian cells however 
have ways to safeguard themselves against the potentially lethal effects of cancer 
gene mutations; only when several genes are defective does an invasive cancer 
develop (Balmain et al., 2003; Bell, 2010).  In this sense, one would think of 
mutated cancer genes that contribute to, rather than causing cancer. 
 Genomic instability and natural selection have been linked to the 
development of pre-malignant cells.  In order for this group of cells to to reach the 
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biological endpoints characterised by malignant growth, self-sufficiency in 
growth signals, resistance to growth-inhibitory signals, evasion of programmed 
cell death, limitless replicative potential, sustained angiogenesis and tissue 
invasion and metastasis must occur (Hanahan and Weinberg, 2000; Sieber et al., 
2003).  With mutation and genomic instability working hand-in-hand, 
spontaneous and environmental DNA damage occur.  These play important roles 
in the initiation and progression of neoplasms.  On the other hand, cells do exhibit 
biological responses that will protect them from the consequences of mutations, 
most critically those that bring about cell cycle arrest and/or cell death.  The cell 
cycle arrest checkpoints provide time for DNA repair before cell cycle 
progression is resumed, or if the damage is too extensive, apoptosis will be 
activated (Friedberg et al., 2004). 
 Mutations that lead to defective DNA sensing mechanism can also 
compromise the cell’s DNA damage response.  This can result in malignant 
transformation as observed in disorders like ataxia telangiectasia (AT), Li-
Fraumeni syndrome, Nijmegen breakage syndrome and Fanconi anaemia 
(Motoyama and Naka, 2004).  These include genes that encode for protein kinases 
like ATM (Ataxia-telangiectasia-mutated) and ATR (Ataxia telangiectasia and 
Rad3 related)  and their downstream effector kinases like Chk1 and Chk2; and 
transcription factor p53 that can convey the damage signal to the various 
pathways that implement appropriate biological activities like DNA repair, cell 
cycle arrest and apoptosis (Shiloh, 2003).   
 Although the majority of cancers are triggered by mutational events, it is 
still not fully understood how cancer cells acquire so many mutations and 
chromosomal abnormalities that are observed in most cancers (Loeb et al., 2008).  
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There is evidence that genetic instability in cancers exists at two levels.  The first 
form of instability is observed at the nucleotide level in a small subset of cancers 
which results in base substitutions or deletions or insertions of a few nucleotides.  
The second form of instability which is observed in most cancers is at the 
chromosomal level that results in losses and gains of whole chromosomes or part 
of (Lengauer et al., 1998).  Chromosomal instability in some cancers leads to 
aneuploidy and a loss of heterozygosity which is associated with the inactivation 
of tumour suppressor genes (Michor et al., 2005). 
 Thus cancer cells can be viewed as cells that possess “mutator phenotype” 
to makes them more susceptible to small mutations which affect their growth 
regulatory genes (Bignold, 2004; Loeb, 1991).  A second possibility in cancer 
initiation is that cancer cells start out more prone to genomic instability compared 
to normal cells.  Mutations in these cells occur at a normal rate, but due to certain 
epigenetic events, they divide at a higher frequency rate compared to normal cells, 
thus leading to an accumulation of genetic mutations within this group of cells 
(Tysnes and Bjerkvig, 2007). 
 
1.1.3 Alterations in cancer genomes and signal transduction 
 Mutations to proto-oncogenes lead to the constitutive expression of these 
genes in cells which are not seen in the wild-type genes.  Oncogene mutation and 
activation can result from chromosomal translocations, gene amplification or from 
subtle intragenic mutations affecting crucial resides that regulate the activity of 
the gene product (Nambiar et al., 2008).  
 Mutations to tumour-suppressor genes work in the opposite way to that 
seen in oncogenes, namely a reduction in gene products or activities is observed.  
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Such inactivation arise from missense mutations at sites that are essential for 
tumour-suppressor activity, mutations that lead to the formation of truncated 
protein and also from deletions or insertions or epigenetic silencing of these genes 
(Negrini et al., 2010).   
 Oncogene and tumour-suppressor gene mutations result in similar 
activities; neoplasms in which cells are stimulated to undergo cell division and at 
the same time inhibiting cell death or cell cycle arrest.  This increase in cell 
number is caused by activating genes that drive the cell cycle and inhibiting 
normal apoptotic processes or by facilitating the provision of nutrients to cells 
through enhanced angiogenesis.   
 The third group of genes termed stability genes or caretakers also 
promotes tumourigenesis when altered.  However they promote tumourigenesis in 
a different manner compared to oncogenes and tumour-suppressor genes 
(Maynard et al., 2009; Rassool et al., 2007; Wimmer and Etzler, 2008) .  Stability 
genes include those involved in DNA repair that are called into action to perform 
mismatch repair, nucleotide-excision repair and base-excision repair. 
 Mutation to these three groups of genes can occur in the germline or to a 
single somatic cell.  The former will result in a genetic disposition to cancer and 
in the latter to sporadic tumours (Volgelstein and Kinzler, 2004).  As a result of 
intensive cancer research over the past decade, it is established that cancer-gene 
mutation affects critical pathways which results in tumourigenesis.  For instance, 
several cancer genes directly control the retinoblastoma (Rb) pathway that 
controls cell division.  These include the genes that encode for proteins that are 
involved in the transition from a resting stage (G0 or G1) to a replicating stage (S) 
of the cell cycle like cyclin dependent kinase 4  (cdk4),  cyclin D1,  pRb and p16 
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(Classon and Harlow, 2002; Ortega et al., 2002; Sherr, 2000).  In this instance, the 
genes encoding Rb and p16 are tumour suppressor genes inactivated by mutation 
and cdk4 and cyclin D1 are oncogenes activated by mutation.  A second well 
documented pathway affected by alteration to the tumour suppressor genes and 
oncogenes is the one that is controlled by the TP73 protein.  p53 is a transcription 
factor that inhibits cell growth and stimulates cell death when induced by cellular 
stress (Oren, 2003; Prives and Hall, 1999; Vogelstein et al., 2000).  Disruption of 
this pathway can be brought about by a mutation to the p53 gene that inactivates 
its ability to bind specifically to its cognate recognition sequence, amplification of 
the MDM2 gene and infection with DNA tumour viruses  whose products bind to 
p53 and inactivate it (Volgelstein and Kinzler, 2004). 
 In addition to the Rb and p53 pathways, there are other pathways that have 
a role in many tumour types including those that involve adenomatous polyposis 
coli (APC) (Kwong and Dove, 2009; Wasch et al., 2010), glioma-associated 
oncogene (GLI) (Liao et al., 2009; Lo et al., 2009), hypoxia-inducible 
transcription factor-1 (HIF-1) (Dales et al., 2010; Kimbro and Simons, 2006) , 
phosphoinositide 3-kinase (PI3K) (Carnero, 2010; Courtney et al., 2010), SMADs 
(Nagaraj and Datta, 2010; Yang and Yang, 2010) and receptor tyrosine kinases 
(RTKs) (Rosell et al., 2010; Saif, 2010). 
  
1.2 Nasopharyngeal carcinoma 
 Nasopharyngeal carcinoma (NPC) is a head and neck cancer of epithelial 
origin.  Although it occurs sporadically in the western hemisphere, it is  endemic 
in South China and Southeast Asia with an incidence rate of between 15 and 50 
per 100 000  in man (Ho, 1978).  There is an intermediate incidence among the 
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Alaskan Eskimos (Nutting et al., 1993), Arabs of North Africa (Parkin et al., 
1997) and parts of the Middle East (Steinitz et al., 1989).  Chinese emigrants 
exhibit a high incidence of this disease but the rate among ethnic Chinese born in 
North America is lower than their counterparts in China (Buell, 1974).  These 
studies imply that both environmental and genetic factors play important roles in 
the development of NPC.  One of the environmental factors is a diet consisting of 
preserved food, particularly at an early age (Armstrong et al., 1998; Yu and 
Henderson, 1987; Yu et al., 1988; Yuan et al., 2000).  These findings have been 
further verified when rats fed with preserved food like salted fish developed nasal 
cavity carcinoma in a dose-dependent manner (Zheng et al., 1994).  A change in 
lifestyle due to rapid economic development which leads to a decrease in intake of 
preserved food has resulted in a statistically significant decrease in incidence rate 
of NPC in Singapore and Hong Kong (Luo et al., 2007).   
 Certain human leucocyte antigen (HLA) subtypes have been associated 
with NPC indicating a strong genetic factor in the development of NPC 
(Goldsmith et al., 2002; Tse et al., 2009; Yu et al., 2009). 
 NPC is classified based on histology into three types (Shanmugaratnam 
and Sobin, 1991).  Type 1 NPC is a keratinising squamous carcinoma which is 
characterised by the presence of well-differentiated cells that produce keratin.  
Type 2 is a non-keratinising squamous carcinoma with cells of varying degree of 
differentiation but does not produce keratin.  Type 3 is also a form of non-
keratinising squamous carcinoma but is less differentiated, with highly variable 
cell types.  Types 2 and 3 NPC are Epstein-Barr virus (EBV) associated and have 
better prognoses compared to Type 1.  However, recent data indicate that most 
NPC tumours, regardless of their histologic subtype, have comorbid EBV 
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infections, demonstrating a close association between EBV infection and NPC 
(Burgos, 2005; Raab-Traub, 2002).  The presence of EBV latent genes encoding 
for the latent membrane proteins (LMP1, LMP2A and LMP2B) and EBV-
determined nuclear antigens (EBNA1 and EBNA2) are prevalently expressed in 
NPC (Tsao et al., 2002).  Moreover, LMP1, an oncogene that brings about cell 
immortalisation is present in 80 – 90% of NPC tumours (Lin et al., 2001). 
 The carboxyl-terminal region of LMP1 has been demonstrated to up-
regulate pathways that promote cellular proliferation like the PI3K/Akt, NF-B 
(nuclear factor-kappa B), MAP (mitogen-activated protein)) kinase, ERK 
(extracellular signal regulated kinase), p38 and JNK (Jun N-terminal kinase) and 
JAK/STAT (signal transducer and activator of transcription) (Shi et al., 2006).  
Activation of transcription factors downstream of these pathways including NF-
B and -catenin leads to uncontrolled cell proliferation via c-Myc (Luo et al., 
1997), cyclin D1 and cyclin E (Chou et al., 2008; Hwang et al., 2002; Tao et al., 
2005) expressions; and inhibition of tumour suppressor proteins, p16, p27 and p53 
(Chen et al., 2004; Chou et al., 2008; Hwang et al., 2003; Makitie et al., 2003) 
(Figure 1.1).  LMP1-positive cells have greater mobility, leading to higher 
metastatic potential (Ozyar et al., 2004) and faster disease progression (Liu et al., 
2003). 
  













Fig 1.1: Overview of the molecular mechanisms involved in NPC 
development (adapted from (Chou et al., 2008)) 
  
 PI3K is involved in a wide variety of cellular pathway including the 
regulation of cell proliferation via Akt.  Over-activation of PI3K has been 
implicated in numerous cancers including NPC.  In NPC, this over-activation 
occurs by various mechanisms (Morrison et al., 2004).  LMP1 can also activate 
Akt directly (Morrison and Raab-Traub, 2005).  A third possible mechanism is by 
down-regulating the expression of phosphatase and tensin homology (PTEN) 
(Pedrero et al., 2005), an inhibitor of PI3K.  Akt is critical in cell growth and 
survival as it activates the mechanism for cell proliferation and inhibits apoptosis 
and is a key protein in tumourigenesis (Song et al., 2005a). 
 Like in all cancers, development of NPC involves amongst the various 
processes, the deregulation of the cell cycle.  The LMP1 plays a critical role in the 
abnormal deregulation of key proteins in cell cycle regulation.  Proteins that 
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enhanced cell cycle progression like c-Myc, cyclin D1, ERK, epidermal growth 
factor receptor (EGFR) and mutant p53 are up-regulated (Hwang et al., 2002; Luo 
et al., 1997; Yang et al., 2001b).  At the same time, inhibitors of cell cycle like 
p16 and p27 are down-regulated (Hwang et al., 2002; Hwang et al., 2003; Makitie 
et al., 2003). 
 Cyclin D1 is responsible for cell progression through G1 (reviewed in 
Section 1.3 of this chapter).  Over-expression of cyclin D1 allows cells with 
damaged DNA to transverse the G1/S checkpoint without cell cycle arrest, 
thereby increasing the risk of tumourigenesis (Robles et al., 1996; Zhou and 
Elledge, 2000).  In NPC, cyclin D1 is over-expressed (Xie et al., 2000) and this is 
due to constitutive expression of active Ras and Raf proteins, low level of p16, the 
cyclin-dependent kinase (cdk) inhibitor (CKI) of cdk4/6-cyclin D (Kerkhoff and 
Rapp, 1998; Song et al., 2005b).  Moreover, LMP1 induces over-expression of 
EGFR that can directly activate cyclin D1 transcription (Tao et al., 2005). 
 As cdk2-cyclin E controls cell cycle at S phase, deregulation of cyclin E 
expression leads to rapid progression of the cell through this phase and 
consequent increase in chromosomal instability (Spruck et al., 1999).  An increase 
in cyclin E activity had been reported in a number of head and neck tumours, 
including NPC and laryngeal and oral cancers (Ioachim et al., 2004; Tao et al., 
2005).  This increase in cyclin E expression in NPC is due to LMP1-induced 
nuclear location of EGFR, which binds to the promoter of cyclin E and 
subsequent increase in its expression (Tao et al., 2005). 
 NPC is responsive to radiotherapy for which there is a high local control 
rate after radical radiotherapy (RT) (Fang et al., 2007a; Lu and Yao, 2008).  
However, concurrent radiotherapy and chemotherapy (chemoradiotherapy) 
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demonstrates a statistically significant reduction in failure and cancer-specific 
deaths compared with radiotherapy alone (Lee et al., 2010a). Chemotherapeutics 
used in chemoradiotherapy include 5-fluorouracil (5-FU) (Azli et al., 1992), 
vincristine (VCR) (Kwong et al., 2004), docetaxel (DTX) (Ngeow et al., 2010) 
and paclitaxel (PTX) (Chan et al., 2004). 
 While radiotherapy and chemoradiotherapy are the conventional treatment 
for NPC, there are now novel potential treatments that specifically target the 
molecular aberrations of NPC that lead to cell inhibition and apoptosis.  As cyclin 
D1 is up-regulated in NPC, cyclin D1 offers a possible target protein.  
Cyclooxygenase (COX-2) is over-expressed in NPC and inhibitors of this protein 
are able to inhibit the growth of NPC cell lines in a dose-dependent manner by 
reducing the level of cyclin D1 in these cells (Chan et al., 2005).  In addition, 
other novel potential agents for NPC control and management includes the 
flavonoids (reviewed in section 1.6 of this thesis). 
 
1.3 Cell cycle 
 The cell cycle consists of two major phases based on morphological 
features observed in cells; the M phase and the interphase.  However, based on 
biochemical features, it comprises the S phase and the M phase with two gap 
phases namely G1 and G2 between the S and M phases (Fig 1.2).  The gap or G 
phases allow cells to ready themselves before entry into the S and M phases.  Cell 
division in eucaryotes is governed by three key proteins; the cyclin-dependent 
kinases (CDKs) and their specific cyclins; and the cyclin-dependent kinase 
inhibitors (CKIs). 
 













Fig 1.2: The cell cycle and the respective control mechanisms (adapted from 




1.3.1 Cdks and their corresponding cyclins as the key regulators of the 
cell cycle 
 
 Active cdk is made up of a protein kinase subunit whose catalytic subunit 
activity requires the presence of a regulatory cyclin subunit.  Cyclins are 
expressed and degraded at specific time during the cell cycle and by this process, 
regulating the kinase activity in a systematic and controlled manner.  Human cells 
possess 13 different loci encoding cdks and 25 loci for cyclins (Malumbres and 
Barbacid, 2005).  However, only a certain subset of cdk-cyclin complexes is 
directly involved in cell cycle progression.  These include the three interphase 
cdks (cdk2, cdk4 and cdk6), a mitotic cdk (cdk1) and 10 cyclins belonging to the 
A, B, D and E type cyclins.  In addition, cell cycle progression requires the 
presence of the cdk7-cyclin H which is also referred to as cdk-activating kinase 
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(CAK) since this complex phosphorylates and activates the various cdk-cyclin 
complexes (Kaldis et al., 1998). 
 The pattern of cyclin expression varies with a cell’s progression through 
the cell cycle and this pattern of specific cyclin expression is an indication of the  
phase of the cell cycle (Grana and Reddy, 1995; Johnson and Walker, 1999) (Fig 
1.2).  In a mammalian cell, cdk4 and cdk6 associated with cyclin Ds will drive the 
cell’s progression through the G1 phase (Matsushime et al., 1992; Meyerson and 
Harlow, 1994).  Cyclin E associates with cdk2 at the G1/S transition to drive the 
cell into the S phase (Koff et al., 1992).  S phase and G2 phase progression are 
driven by the cdk2-cyclin A complex and the cdk1-cyclin A complex respectively 
(Pagano et al., 1992).  Finally, progression of cells through mitosis is dependent 
on cdk1-cyclin B (Nigg, 2001). 
 During the late S and G2 phases of the cell cycle, cells prepare for mitosis 
by up-regulating the level of cyclins A and B.  Both cyclins A and B are able to 
bind to cdk1 separately (Stark and Taylor, 2006).  As the level of cyclin B 
increases, it forms a complex with cdk1 where the complex will remain in the 
cytoplasm.  When cells are ready for mitosis, this complex of cdk1-cyclin B will 
translocate to the nucleus where it will bring about mitosis and cytokinesis 
(Takizawa and Morgan, 2000).  Entry into mitosis is determined by the presence 
and activity of cdk1-cyclin B, which is regulated by its phosphorylation status, 
brought about by activating phosphorylation at Thr
161












 are mediated by cdk-activating kinase (CAK) (Pines, 1995), Myt1 (Liu 
et al., 1997) and Wee1(Parker and Piwnica-Worms, 1992) respectively.  At the 




 residues are dephosphorylated by cdc25, a 
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phosphatase enzyme (Draetta and Eckstein, 1997).  Complete Cdc25 activation 
requires phosphorylation at several sites within the cdc25 amino terminal domain 
and it is catalysed by two kinases; the polo-related kinase (Plk) (Lobjois et al., 
2009) and cdk1-cyclin B (Hoffmann et al., 1993).  The ability of cdk1-cyclin B to 
phosphorylate and activate cdc25 serves as a positive feedback loop. 
 Cdk1-cyclin B activity is also controlled by its sub-cellular location in the 
cell.  During interphase, cdk1-cyclin B is found entirely in the cytoplasm (Pines 
and Hunter, 1991, 1994).  In the late prophase, most cdk1-cyclin B complex will 
be translocated from the cytoplasm to the nucleus (Hagting et al., 1999; Takizawa 
and Morgan, 2000) (Fig 1.3).  Cyclin B is continuously translocated into and out 
of the nucleus with help of an export receptor, Crm1 (Yang et al., 1998).  During 
interphase, the rate of export exceeds the rate of import, leading to an 
accumulation of cdk1-cyclin B in the cytoplasm. 
 Cdc25, like cdk-cyclin B, is also localised in the cytoplasm during 
interphase and will re-localise to the nucleus during prophase.  Localisation of 
cdc25 in the cytoplasm is controlled in part by the rate of import/export between 
the cytoplasm and nucleus.  However during interphase, cdc25 is sequestered in 
the cytoplasm by a phosphoserine-binding protein, 14-3-3 (Peng et al., 1998; Peng 
et al., 1997) (Fig 1.3).  To interact with 14-3-3, cdc25 must be phosphorylated at 
the Ser
216
 residue (in human).  However, little is known about the identity of the 
kinases and phosphatases that act on Ser
216
.  There are strong indications that 
Chk1 and Chk2 are possible candidates as both enzymes are able to phosphorylate 
cdc25 at ser
216 
in vitro.  Moreover, in the presence of DNA damage, Chk1 and 
Chk2 are able to mediate cell cycle arrest at G2 (Furnari et al., 1999; Peng et al., 
1997). 













Fig 1.3: Molecular mechanisms controlling the activation of cdk1-cyclin B 




1.3.2 Substrates of cdks 
 Although numerous cdk substrates have been identified, the detailed 
molecular mechanism on how cdk-mediated phosphorylation has only been well 
characterised for some of these substrates.  Activated cdks are serine/threonine 
kinases whose activities are proline-directed, i.e cdks require a proline adjacent to 
the phosphorylated serine or threonine residue at the carboxyl-terminal (Songyang 
et al., 1994; Songyang et al., 1996; Srinivasan et al., 1995).  In addition, near the 
serine and threonine phosphorylation sites, the recognition motif also possesses a 
positively charged lysine or arginine three positions downstream of the 
phosphorylated site (Songyang et al., 1994; Songyang et al., 1996; Srinivasan et 
al., 1995).     
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 Different cdks may share common substrates but act on different 
phosphorylation sites within the substrate and thus regulating different aspects of 
this substrate function.  A good illustration is the phosphorylation of pRb by cdk4-
cyclin D1 and cdk2-cyclin E (Harbour et al., 1999).  The mechanism underlying 
this selectivity is unclear, but may be linked to the cyclin subunits binding to 
distinct region of pRb. 
 Another mechanism to control cdk substrate specificity involves 
differential sub-cellular localisation of the cdks and their cyclins.  Newly 
synthesised cyclins E and A will localise and complex with their respective cdks 
in the nucleus and thus act on substrates in the nucleus (Ohtsubo et al., 1995; 
Pines and Hunter, 1991).  In the case of cyclin B1, it is translocated between the 
cytoplasm and nucleus during the cell cycle where synthesis of both cyclins B1 
and B2 is initiated during the interphase and localised in the cytoplasm.  During 
the prophase, cyclin B1 migrates from the cytoplasm to the nucleus but cyclin B2 
remains in the cytoplasm (Draviam et al., 2001; Pines and Hunter, 1994). 
 
1.3.2.1 Cdk substrates at the G1-S phase 
 The major cdk4/6-cyclin D1 substrate is pRb (Ezhevsky et al., 2001; 
Lundberg and Weinberg, 1998) (Fig 1.4).  pRb, a tumour suppressor prevents cell 
entry into the G1/S cell progression by inhibiting the transcription factor E2F 
(Attwooll et al., 2004); and this inhibitory effect can be lifted by cdk4/6-cyclin 
D1-mediated phosphorylation (Adams, 2001).  Initial phosphorylation of pRb by 
cdk4/6-cyclin D complexes leads to partial activation of E2F, which allows for the 
transcription of the cyclin E gene by the E2F transcription factor (Geng et al., 
1996).  The newly synthesised cyclin E interacts and activates cdk2 which will 
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further phosphorylate pRb, resulting in the complete activation of E2F.  The 
active E2F will subsequently up-regulate the expression of numerous genes for 
cell cycle progression and these include CDC6 (Hateboer et al., 1998); DHFR 
(dihydrofolate reductase) (Blake and Azizkhan, 1989; Noe et al., 1997); TK 
(thymidine kinase) (Dou et al., 1994);  DNA polymerase  (Izumi et al., 2000); 
and cyclin E (Geng et al., 1996).   
 Cdk4/6-cyclin D and cdk2-cyclin E inactivate pRb through sequential 
phosphorylation at different sites, resulting in the progressive loss of pRb-
mediated E2F inhibitory function.  The initial phosphorylation by cdk4/6-cyclin D 
occurs at the amino acid position 788 and 795 of pRb, which destabilises its 
interaction with E2F (Rubin et al., 2005) and subsequent dissociation from histone 
deacetylases (HDACs) (Ferreira et al., 2001) (Fig 1.4).  Subsequent 
phosphorylation of pRb during late G1 phase by cdk2-cyclin E leads to complete 
dissociation of E2F from the pRb-E2F complex (Harbour et al., 1999) (Fig 1.4). 
 Cdk2-cyclin E is also involved in the phosphorylation and activation of 
NPA (nuclear protein mapped at the AT locus), an important regulator in histone 
expression and synthesis (Zhao et al., 1998).  
 Centrosomes play a central role in sister chromatid segregation during 
mitosis.  Following cytokinesis, each daughter cell inherits one centrosome.  
Therefore before mitosis, it is necessary to duplicate the centrosome.  Cdk2-cyclin 
E initiates centrosome duplication by phosphorylating the centrosomal proteins 
NPM/B23 (nucleophosmin) and CP110 (centrosomal protein of 110 kDa) which 
allows the dissociation of NPM/B23 from the centrosome and subsequent 
duplication (Okuda et al., 2000; Tokuyama et al., 2001). 
 












Fig 1.4: Inhibition of pRb activity by cdk4/6-cyclin D and cdk2-cyclin E 




1.3.2.2 Cdk substrates at the S phase 
 As cells enter the S phase, DNA replication is initiated at numerous origins 
simultaneously.  Each DNA replication origin consists of initiator proteins 
collectively termed ORC (origin recognition complex)  which will interact with 
replicator elements within the DNA (Hamlin et al., 1994).  The ORC serves as a 
base for protein-protein interactions to bring about DNA replication.  In order to 
prevent polyploidy in cells, DNA is not allowed to replicate twice in the S phase 
and this is regulated by the cdks.  Phosphorylation status of ORC changes 
throughout the cell cycle, with the ORC being hypophosphorylated during the 
early G1 and increasingly being phosphorylated as cells progress from the G1 to S 
phase (Li et al., 2004).  Several proteins which regulate the ORC are also 
phosphorylated by the cdks.  For instance, cdk1-cyclin A phosphorylates the ORC 
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subunit Orc1 during mitosis, thus preventing its interaction with chromatin (Li et 
al., 2004). 
 
1.3.2.3 Cdk substrates at the M phase 
 Progression through mitosis is governed mainly by cdk1-cyclin B.  It is 
inactivated during the late mitosis in order for cell cycle exit.  APC/C (anaphase-
promoting complex/cyclosome) ubiquitin ligase is a major target of cdk1-cyclin 
B.  Activation of APC/C by phosphorylation is initiated in late mitosis by cdk1-
cyclin B (Kraft et al., 2003) and this allows subsequent interaction between the 
phosphorylated protein with one of two activator proteins, cdc20 or cdh1 (cdc20 
homologue 1).  Once activated, APC/C
cdc20
 (complex formed between APC/C and 
cdc20) initiates the ubiquitination and proteasomal degradation of securin, an 
anaphase inhibitor protein that blocks sister chromatid separation and activation of 
separase, an enzyme that allows the separation of the two sister chromatids 
(Hagting et al., 2002; Hauf et al., 2001).  A third substrate of APC/C
cdc20
 is the 
cdk1-cyclin B, that will result in phosphorylation and subsequent proteasomal 
degradation of this cdk complex in the late anaphase, thus relieving the 
phosphorylation of cdh1 by cdk1-cyclin B (King et al., 1995).  This allows cdh1 
to interact with APC/C forming the APC/C
cdh1
 which is responsible for spindle 
assembly and spindle elongation and subsequent cytokinesis (Floyd et al., 2008). 
 Cdk1-cyclin B can also phosphorylate and activate Emil (early mitotic 
inhibitor) which interacts with cdc20 and inhibits APC/C, resulting in mitotic 
arrest (Reimann et al., 2001).  Emil accumulates before mitosis and will be 
ubiquitinated and degraded during mitosis by the SCF (Skp, Cullin, F-box 
containing complex) ubiquitin ligase complex (Margottin-Goguet et al., 2003). 
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1.3.3 Cdk inhibitors (CKIs) 
 The inhibition of cdk activities by CKIs constitutes an important 
mechanism in cell cycle control and provides an integral link to other signalling 
pathways during cellular proliferation, differentiation and senescence (Ju et al., 
2007; Peter, 1997). 
 
1.3.3.1 The INK4 family of CKIs 
 The INK4 family of CKIs specifically targets the cyclin D-dependent 
kinases.  There are four proteins under this family; p16
INK4A
 (Serrano et al., 1993), 
p15
INK4B 
(Hannon and Beach, 1994), p18
INK4C 
(Hirai et al., 1995)  and p19
INK4D
 
(Hirai et al., 1995); all of which compete for binding with cyclin D to cdk4 and 
cdk6  (McConnell et al., 1999; Sherr and Roberts, 1999).  The association 
between the INK4 family of proteins for cdk4 and cdk6 is very specific and is 
dependent on the presence of pRb in the cell.  In the absence of pRb, cyclin E 
expression and inhibition of cdk4-cyclin D complexes does not arrest cell cycle 
progression at the S phase (Lukas et al., 1997).   
 Among the INK4 family of proteins, p16
INK4A





protein inhibits cell cycle progression by stabilising the 
complex between p53 and MDM2 (Weber et al., 1999) .  Expression of p14
ARF
 is 
regulated by E2F, a transcription factor controlled by pRb.  E2F is also the 
transcription factor for cyclins E and A, whose proteins are key proteins in S 
phase.  Loss of p16
INK4A
 is functionally equivalent to loss of pRb whereas the loss 
of P14
ARF 
is analogous to loss of p53 (James and Peters, 2000; Sherr, 2001).  Both 
pRb and p53, being tumour suppressors are critical proteins in the regulation of 
cell division and apoptosis. 




regulates cell cycle at the G1 phase by inhibiting cdk4/6-cyclin D 
in response to cytokines like transforming growth factor- (TGF-) (Hannon and 
Beach, 1994).  The p15
INK4B
-mediated G1/S cell arrest is often deregulated in 
numerous human cancers like prostate cancer, melanoma, pituitary adenoma, 
acute myeloid leukaemia and gastric cancer (Shima et al., 2005; Solomon et al., 
2008) . 





expressed during foetal development and play key roles in terminal cellular 
differentiation (Zindy et al., 1997). 
 
1.3.3.2 The CIP/KIP family of CKIs 







 (reviewed by (Besson et al., 2008)).  These member proteins bind 
specifically and inhibit both cyclin and cdk subunits through conserved motifs for 
cdk and cyclin binding in the amino termini of the inhibitors (Adams et al., 1996; 
Chen et al., 1996).  p21, p27 and p57 expressions are up-regulated during 
development and differentiation; and also in response to cellular stresses.  
However, the elevated expression of each member is due to different anti-
proliferative signals.  For instance, p21 is elevated in p53 mediated cell cycle 
arrest in response to DNA damage, resulting in cell arrest in G1 and G2 (el-Deiry 
et al., 1993).  p27 on the other hand is up-regulated in mitogen-deprived cells 
(Besson et al., 2007). 
 Although the CIP/KIP protein members are found to act preferentially on 
cdk2 complexes and inhibiting these complexes (Russo et al., 1996), they can also 
activate cdk4/6-cyclin D by aiding with the assembly of catalytically active 
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cdk4/6-cyclin D (Cheng et al., 1998).  The latter activity allows the downstream 
activation of cdk2-cyclin E (Perez-Roger et al., 1999).  However there are also 
reports indicating the inhibitory effects of CIP/KIP proteins on the cdk4/6/-cyclin 
activity (Kato et al., 1994), thus demonstrating that the effects of these CKIs on 
cdk activities can be modulated by other factors. 
 The key function of p21
CIP1 
in cell cycle regulation is its ability to inhibit 
the activity of the cdk2-cyclin A and E which are required for G1/S transition; 
leading to G1cell arrest.  p21
CIP1
 expression is enhanced in p53-dependent DNA 
damage which will lead to G1 cell arrest following exposure to DNA damaging 
agents in wild-type p53-  but not in p53- mutant expressing cells ((Dulic et al., 
1994).  p21
CIP1 
can associate and inhibit PCNA (proliferating cell nuclear 
antigen), a subunit of DNA-polymerase  and preventing DNA replication in 
committed cells (Luo et al., 1995).  Besides its involvement in cell cycle, p21
CIP1
 
also acts as a negative regulator of p53-dependent apoptosis.  One possible 
mechanism is via its inhibition of cdk like cdk2-cyclins A and E, resulting in G1 
cell arrest and subsequent apoptosis (Gartel and Tyner, 2002).  A second possible 
mechanism is via its interaction with pro-apoptotic molecules such as procaspase-
3 and procaspase-8 at the amino-terminus which prevents the subsequent 
degradation of the procaspases to the active caspases (Suzuki et al., 1998) . 
 The second member of the CIP/KIP family is p27
KIP1
, an inhibitor of cdk2-
cyclin E and therefore plays a role as a negative regulator at the G1/S transition.  
The activity of p27
KIP1 
is controlled by its level of expression during the cell cycle.  
Its concentration decreases and increases in response to mitogen stimulation and 
mitogen deprivation respectively (Hengst and Reed, 1998).  Numerous reports 
indicate that p27
KIP1
 through its fluctuating concentration in the cells plays a 
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central role in the decision by the cells to either commit to cell division or 
withdrawal (Coats et al., 1996).  A second role of p27
KIP1
 has also been reported 
in which it is able to exert an inhibitory effect on apoptosis in cells (Levkau et al., 
1998).  Numerous studies have linked the induction of the CIP/KIP proteins and 
subsequent downstream anti-apoptotic effect to the development of resistance to 
apoptosis induced by cytotoxic drugs and irradiation (De la Cueva et al., 2006; St 
Croix et al., 1996). 
 The last member of the CIP/KIP protein, p57
KIP2
 plays a key role in 
embryonic development; and down-regulation of its expression leads to 
developmental disorder (Yan et al., 1997; Zhang et al., 1997). 
 
1.3.4 Cell cycle checkpoints 
 Mammalian cells are committed to cell division during mid G1, termed the 
restriction checkpoint, following phosphorylation and inactivation of 
retinoblastoma (pRb) protein and the release of E2F (Beijersbergen and Bernards, 
1996).  Free E2F, a transcription factor of cyclins E and A brings about S phase 
cell progression (Harbour and Dean, 2000b; Obeyesekere et al., 1995).  To allow 
the cell to progress in an orderly manner through S phase and to initiate the G2 
phase, E2F must be inactivated.  This is brought about by cdk2-cyclin A binding 
to and phosphorylating the E2F-DP complex, in the process inactivating its DNA 
binding ability (Xu et al., 1994).  There is a checkpoint at S phase termed the 
replication checkpoint.  This checkpoint will monitor DNA synthesis and prevent 
cells from progressing to the G2 phase and M phase if the newly synthesised 
DNA was found to be defective.  This checkpoint is controlled by a group of 
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proteins namely ATM, ATR, Chk1 and Chk2 (Falck et al., 2001; Zhou and 
Elledge, 2000). 
 The same group of enzymes (ATM, ATR, Chk1 and Chk2) also 
controlsanother checkpoint mediated by p53.  p53 is a regulator that responds to 
stress signals like DNA damage and subsequent cell cycle arrest (Levine, 1997).  
The level of p53 in normal cells is kept low, owing to rapid ubiquitin-dependent 
degradation mediated by the E3 ubiquitin ligase MDM2 (Brooks and Gu, 2004).  
Various stresses like DNA damage caused by UV exposure can inhibit MDM2 
degradation of p53.  This is mediated by phosphorylation of p53 catalysed by 
ATM, ATR, Chk1 and Chk2 at different amino acid sites (Banin et al., 1998; 
Chehab et al., 2000; Urist et al., 2004).  Once stabilised p53 can elicit several 
different cellular responses including cell cycle arrest via up-regulation of p21 
(Choisy-Rossi et al., 1998) and the induction of apoptosis via up-regulation of 
pro-apoptotic protein, Bax (Miyashita and Reed, 1995). 
 
1.3.5 Deregulation of the cell cycle and cancer development 
 Cell cycle progression is an ordered and tightly-regulated process.  It  
involves multiple pathways and checkpoints to assess both the extracellular and 
intracellular signals that a cell receives.  These signals govern the different cell 
cycle phases which will influence the cell’s decision to proliferate or to arrest 
cellular growth, to undergo DNA repair or apoptosis.  Hence these signals in the 
form of proteins can be positive or negative regulators of the cell cycle 
progression.  When a cell is unable to respond to signals due to genetic instability, 
it will lead to aberrant cell proliferation and perpetuate its genetic instability 
further.   Tumourigenesis will initiate when there is abnormal expression and 
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activation of positive regulators and suppression of negative regulators.  Hence, 
understanding the molecular mechanisms leading to the deregulation of the cell 
cycle progression in cancer can provide vital and important insights into how 
normal cells become tumourigenic in the hope that new cancer treatment 
strategies can be formulated. 
 Numerous reports have demonstrated that tumourigenesis is frequently 
associated with mutation and or abnormalities in the expression of the cyclins and 
their associated cdks and CKIs.  Over-expression of cdk4 although less frequent 
than the over-expression of cyclins have been identified in cell lines of myeloma 
(Menu et al., 2008), glioblastoma (Michaud et al., 2010) and pharyngeal 
squamous cell carcinoma (Koontongkaew et al., 2000).  Over-expressions of cdk1 
and cdk2 have also been reported in other studies (Kim et al., 1999; Liao et al., 
2004; Zhou et al., 2003). 
 One of the best explored examples of a cyclin that contributes towards 
tumourigenesis is the over-expression of cyclin D in cancers of the breast, 
oesophageal, bladder, lung and squamous cell carcinomas (Chou et al., 2008; Hall 
and Peters, 1996; Koontongkaew et al., 2000; Landberg, 2002).   Over-expression 
of cyclin E has been demonstrated in breast and colon cancer; nasopharyngeal 
carcinoma and in acute lymphoblastic and acute myeloid leukaemia (Chou et al., 
2008; Iida et al., 1997; Kitahara et al., 1995; Nielsen et al., 1997; Scuderi et al., 
1996).   The up-regulation of cyclin A is not only observed in cancer but it is also 
an indicator of poor prognosis (Bukholm et al., 2001; Ekberg et al., 2005; Husdal 
et al., 2006). 
 Cdc25 family of cdk activators acts as a phosphatase, dephosphorylating 
cdk.  Cdc25A activates the cdk at the G1/S transition phase, cdc25B at the S 
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phase and the last member of the family, cdc25C activates cdk1-cyclin B during 
entry into mitosis.  Deregulation of the cdc25 proteins through over-expression 
has resulted in  tumour formation (Cangi et al., 2008; Kristjansdottir and Rudolph, 
2004; Loffler et al., 2003; Xing et al., 2008). 
 CKIs are able to inhibit the cdk activities and subsequent growth inhibition 
through pRb activation.  Mutation to p16
INK4A
 has led to the development of 
numerous human cancers (Demirhan et al., 2010; Krasinskas et al., 2010; Panani 
et al., 2009; Wiesner et al., 2010). Cells with mutated p16
INK4A 
would proceed 
through G1 without any restraint.  Both p16 and p15 gene loci are located closed 
to each other on chromosome 9 of the human genome and deletion of p16 gene 
leads to p15 deletion as well (Bostrom et al., 2001; Hallor et al., 2008; Southgate 
et al., 1995).  Thus similar effect that one observed after  p16 deletion will also be 
observed after p15 deletion.  Mutation to p19, another member of the INK4 
family of CKIs leads to subsequent deregulation of p53 (Debies et al., 2008; 
Moore et al., 2003).   
 Disruption to and subsequent loss of p27
KIP1
 expression has been reported 
in human cancer of the lung (Pateras et al., 2006), breast (Chappuis et al., 2000) 
and bladder (Adachi et al., 2003) and is also an indicator of poor prognosis and 
tumour aggressiveness (Hommura et al., 2000; Zhu et al., 2004).   Numerous 
reports have also demonstrated the implication of p21
CIP1
 down-regulation to 
tumourigenesis caused by mutation in p53 (Kiyosaki et al., 2010; Liu et al., 2010; 
Wilson et al., 2008).   
 pRb is the most important cdk substrate at the G1 phase and numerous 
reports have linked mutation of this gene to cancer.  The family members of pRb 
have been linked to cell cycle events like clonal expansion, terminal cell cycle 
Page | 28  
 
exit, maintenance of the post-mitotic state and the induction of tissue-specific 
gene expression and the regulation of apoptotic events (Classon and Dyson, 







, cdk2, cdk4/6, cyclins A, E and D.  Mutations and 
deletions of the Rb genes result in the inactivation of their biological function as 
tumour suppressors and thus lead to an increased susceptibility to tumourigenesis 
(Dunn et al., 1988).  As a direct consequence of the mutation and deletion of the 
Rb genes, E2F transcription factors are liberated from pRb control, leading to 
deregulation of the cell cycle (reviewed by (Scambia et al., 2006)).  Binding 
between pRb and E2F can also be disrupted by DNA tumour virus oncoprotein 
like papilloma virus E7 which binds to pRb and consequently releases E2F as 
observed in cervical cancer and mesothelioma (Helt and Galloway, 2003; Kalejta, 
2004; Shah, 2004).   
 Inappropriate pRb phosphorylation due to enhanced cdk4/6-cyclin D 
activity (over-expression of cyclin D) contributes towards the development of 
parathyroid adenomas, B-cell lymphomas and squamous cell carcinoma (Brizova 
et al., 2008; Fernandez et al., 2005; Rydzanicz et al., 2006).   pRb activity is 
affected indirectly by p16
INK4A
 as the latter binds and inhibits cdk4/6-cyclin D and 
thus maintains the tumour suppressor activity of pRb through the inhibition of 
E2F.  The loss of p16
INK4A
 will inhibit Rb activity, and thus result in 
tumourigenesis as well (Mitchell et al., 2003). 
 A second tumour suppressor gene that has high frequency of mutation in 
cancers is the p53 gene (reviewed by (Brosh and Rotter, 2009; Brown et al., 
2009)).  p53 is a sequence-specific DNA-binding protein that is up-regulated in 
the presence of DNA damage and is able to induce cell cycle arrest or apoptosis at 
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the checkpoints of the cell cycle.  Point and missense mutations lead to 
conformational changes and subsequent inactivation of this protein (Gannon et al., 
1990; Milner, 1991).  Binding of p53 to viral oncoproteins like SV40 T antigen, 
HPV E6 and adenovirus E1B-55K can also inactivate p53 function (Chen and 
Defendi, 1992; Crook and Vousden, 1994; Yi et al., 2009)   
 One can conclude that a breakdown of cell cycle due to a deregulation 
brought about by oncogenes encoding cyclins and cdks; tumour suppressor genes 
like Rb and p53; and genes encoding for CKIs whose function tether on the 





 Apoptosis is a highly regulated physiological process of cell death, critical 
in the maintenance of tissue homeostasis in multicellular organisms.  It is 
triggered by a variety of extrinsic and intrinsic signals.  One of the major causes 
of tumourigenesis is the deregulation of apoptotic mechanisms in cells, which 
leads to cell accumulation and the loss of ability of multicellular organisms to 
maintain cell turnover.   
 
1.4.2 Morphological and biochemical features in apoptotic cells 
 Apoptosis can be captured in a sequence of morphological changes 
observed in cells including chromatin condensation, cytoplasmic shrinkage, 
plasma membrane blebbing and eventually the formation of membrane-enclosed 
particles termed apoptotic bodies which contain intact organelles as well as a 
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portion of the nucleus (Rich et al., 1999).  These apoptotic bodies are 
subsequently ingested and degraded by phagocytes and neighbouring cells, 
preventing inflammation or tissue scarring.  Hence apoptosis is well suited to 
maintain normal cell turnover during embryogenesis and in adult tissues 
(Jacobson et al., 1997).  This is in contrast to necrosis, which is a pathological 
mode of cell death brought about by irreversible swelling of the cytoplasm and 
distortion of the organelles like mitochondria.  Cell death ensues when the cell 
loses its membrane integrity resulting in cell lysis.  Due to the release of cellular 
contents to the extracellular space, inflammation will develop in the surrounding 
tissue.  Necrosis is seen when cells are exposed to toxic stimuli such as 
hyperthermia, metabolic poisons and direct cell trauma (Kanduc et al., 2002; 
Proskuryakov and Gabai, 2010).  The decision of the cell to die by necrosis or 
apoptosis is thought to depend mainly on the severity of the damage to cells 
(Ankarcrona et al., 1995) and intracellular ATP concentration (Leist et al., 1997).  
Other forms of cell death have also been reported in recent years, including 
autophagy, paraptosis, necroptosis and oncosis (Degterev et al., 2005; Leist and 
Jaattela, 2001; Okada and Mak, 2004; Yang and Klionsky, 2009). 
 Biochemical changes observed in cells undergoing apoptosis include the 
externalisation of phosphatidylserine (PS) residues, activation of caspases and 
nuclear DNA fragmentation (Hengartner, 2000).  However, cell death by 
apoptosis independent of caspases has also been observed in some cells (Leist and 
Jaattela, 2001). 
 There are two main pathways of caspase-mediated cell death and they are 
the extrinsic or death receptor-mediated pathway and the intrinsic or 
mitochondria-dependent pathway.  The former plays a fundamental role in the 
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maintenance of tissue homeostasis and the latter is used extensively by cells in 
response to extracellular signals and internal stimuli like DNA damage. 
 
1.4.3 Caspases 
 Caspases belong to a group of cysteine-dependent aspartate-specific 
proteases which are involved in the initiation and execution of apoptosis 
(Thornberry and Lazebnik, 1998).  The human genome encodes for caspases 
designated caspase-1 to caspase-10 and caspase-14 (Alnemri et al., 1996).  
Caspases are synthesised as inactive zymogens termed procaspases containing a 





Fig 1.5: Domain organisation of caspases (adapted from (Li and Yuan, 2008)) 
  
 Caspases are classified into two groups based on the lengths of their 
prodomains, which also correspond to their position within the apoptotic 
signalling pathway.  These two groups include the initiator caspases (caspase -1, -
2, -4, -5, -8, -9, -10, and -11) and effector caspases (caspase -3, -6, and -7).  
Initiator caspases possess long prodomains that may either contain the death 
effector domain (DED) or the caspase recruitment domain (CARD) (Fig 1.5) 
(Hofmann et al., 1997).   These initiator caspases generally act upstream of the 
small prodomain-containing effector caspases (Ashkenazi and Dixit, 1998; 
Nicholson and Thornberry, 1997).  Effector caspases with their short prodomains 
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perform downstream execution steps of apoptosis by causing proteolysis of 
cellular substrates. 
 In the procaspase forms, they exhibit low intrinsic enzymatic activity.  
Cleavage of the procaspase leads to the formation of three fragments; one large 
(p20) and one small (p10) catalytic subunits and the prodomain.  The two protease 
subunits associate with each other to form a heterodimer and two such 
heterodimers further complex to form a tetramer, which now possesses the active 
form of caspases (Walker et al., 1994). 
 The induction of apoptosis results in the activation of initiator caspases, 
and once activated, they will activate the downstream effector caspases in a 
cascade-like pattern (Slee et al., 1999).  The effector caspases subsequently act on 
a series of substrates including inhibitor of caspase-activated DNase (ICAD), 
poly(ADP-ribose)polymerase (PARP) and other proteins that bring about cellular, 
morphological and biochemical changes of apoptosis (Cohen, 1997).   
 
1.4.4 The extrinsic apoptotic pathway 
 Cell surface death receptors (DRs) belong to the tumour necrosis factor 
receptor (TNFR) superfamily.  They initiate the apoptotic biochemical signalling 
pathway following binding of death ligands.  DR proteins are characterised by the 
presence of multiple cysteine-rich repeats in the extracellular domain and the 
death domain (DD) found at the cytoplasmic tails of the receptors.  The members 
of the DR family include Fas (also known as DR2, APO-1 and CD95), TNFR1, 
DR3 (also known as APO-3, LARD, TRAMP and WSL1), TRAIL1 (TNF-related 
apoptosis-inducing ligand receptor 1) (also known as DR4 and APO-2), TRAIL2 
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(also known as DR5, KILLER and TRICK2), DR6, EDAR (ectodysplasin A 
receptor) and nerve growth factor receptor (Lavrik et al., 2005). 
 One of the best studied DR is Fas, a 319-amino acid transmembrane 
glycoprotein (Itoh et al., 1991).  Each receptor possesses three extracellular 
regions with cysteine-rich repeats domains and a conserved 80-amino acid long 
region located in the carboxyl-terminus which is found among the DRs.  This 
region is termed death domain (DD) and plays critical role in the downstream 
signalling pathway as well as its role in the activation of the transcription factor 
nuclear factor NF-B (Ashkenazi and Dixit, 1998; Tartaglia et al., 1993).  NF-B 
however prevents apoptosis in cells as it promotes expression of survival factors 
like the IAP (inhibitor of apoptosis) family of proteins. 
  Binding between Fas-FasL leads to receptor oligomerisation (Ashkenazi 
and Dixit, 1998; Wallach et al., 1999).  This is followed by binding of the adaptor 
protein to Fas via the DDs on both Fas and FasL.  FADD (Fas-associated DD) 
protein is an example of an adaptor protein which possesses a DD at its carboxyl-
terminus and a second protein-protein interaction domain, called the death-
effector domain (DED) at its amino-terminus (Chinnaiyan et al., 1996; Muzio et 
al., 1996).  FADD subsequently recruits procaspase-8 to its DED domain when 
the DED or prodomain on procaspase-8 binds to its DED, resulting in the 
formation of the death-inducing signalling complex (DISC) (Fig 1.6).  The 
recruitment and oligomerisation of procaspase-8 to DISC leads to its autocatalytic 
activation; and subsequent activation of a series of downstream caspases as well 
as structural and regulatory proteins, which all culminate in cellular apoptosis 
(Kischkel et al., 1995).   
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 Binding of Fas-FasL leads to two distinct phenomenal events in two 
groups of cells.   In one group of cells, termed Type I cells activation of caspase-8 
is followed by the activation of caspase -3 and -7 (Muzio et al., 1996; Srinivasula 
et al., 1996).  In the second group of cells, designated Type II cells, limited 
activation of caspase-8 results in an amplification loop mediated by mitochondrial 
activation  (Scaffidi et al., 1999b).  In this case, caspase-8 cleaves Bid, a cytosolic 
BH (Bcl-2 homology)-3-only proapoptotic Bcl (B-cell lymphoma)-2 (Bcl-2) 
family protein member resulting in an active but truncated Bid (tBid) which is 
now able to translocate to the mitochondria to activate the downstream signalling 
proteins of the mitochondrial apoptotic pathway (Li et al., 1998; Luo et al., 1998) 
(Fig 1.6).  This demonstrates a co-operation between the extrinsic and intrinsic 
apoptotic pathways (Fig 1.6).  
 In type I cells, the activation of caspase-8 triggers the cleavage of 
downstream caspases such as caspase-3 whose target is the inhibitor of caspase-
activator deoxyribonuclease (CAD) (ICAD) (Enari et al., 1998).  CAD is an 
endogenous endonuclease and is kept in an inactive form in the cytosol by its 
inhibitor, ICAD.  Active caspase-3 cleaves and inactivates ICAD and in the 
process, releasing CAD from its inhibitory partner (Sakahira et al., 1998).   The 
liberated CAD subsequently enters the nucleus and degrades the cell’s 
chromosomal DNA, leading to DNA fragmentation and cell death; both events 



















Fig 1.6: The Fas signalling pathway (adapted from (Ashe and Berry, 2003)) 
  
 A protein inhibitor present in cells is able to inhibit the extrinsic apoptotic 
pathway.  This protein, a 55-kDa inhibitor termed cellular Fas-associated DD-like 
interleukin (IL)-1-converting enzyme inhibitory protein (c-FLIP), is an inactive 
homologue of caspase-8.  It possesses two DEDs and is able to bind to the DED 
of FADD and caspase-8 to block signal transduction of the Fas-induced death 
signal resulting in prolonged cell survival (Irmler et al., 1997; Scaffidi et al., 
1999a).  A homologous viral protein, designated v-FLIP can moderate DR-
initiated apoptotic pathway that involves caspase-8 (Glykofrydes et al., 2000).  In 
some cell types, Fas-induced apoptosis is regulated by mitochondria-associated 
caspases and apoptosis–promoting members of the Bcl-2 family (Scaffidi et al., 





















Fig 1.7: Cooperation between the extrinsic and intrinsic apoptotic pathway 
and the negative regulation by ICAD-CAD complex (adapted from (Ashe and 
Berry, 2003)) 
 
1.4.5 The intrinsic (mitochondria-associated) pathway 
 Mitochondria are the site of eucaryotic oxidative metabolism, used by cells 
for the synthesis of adenosine triphosphate (ATP) via a series of oxidative 
phosphorylation process and cytochrome c.  Mitochondria have also been 
identified to play a critical role in apoptosis.  A number of apoptotic proteins is 
located and compartmentalised within the mitochondrion and following signals 
transduced to the mitochondrion, these proteins are released into the cytosol to 
trigger the intrinsic signal transduction pathway leading to apoptosis.   
 The intrinsic pathways are controlled by the Bcl-2 family of proteins, a 
group of highly conserved proteins which consists of pro-apoptotic and anti-
apoptotic members whose presence at the mitochondrial membrane determine the 
fate of the cells towards cell death or survival (reviewed by (Youle and Strasser, 
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2008).  The two distinct functional groups of Bcl-2 proteins can be differentiated 
by their structural features.  The anti-apoptotic Bcl-2 proteins including Bcl-2, 
Bcl-XL, Mcl-1, Bcl-W and A1 all share two to four conserved regions within the 
polypeptide chains termed the BH (Bcl-2 homology) domains (BH1 to 4) (Danial 
and Korsmeyer, 2004; Strasser, 2005).  They prevent apoptosis by binding and 
inactivating pro-apoptotic proteins through sequestration.  The pro-apoptotic 
group of proteins can be divided into two sub-groups based on their structural 
domains.  The first sub-group is made up of two protein members, namely Bax 
and Bak.  They possess three BH domains (BH1 to 3) and will induce apoptosis 
when over-expressed  (Danial and Korsmeyer, 2004).  The second sub-group of 
pro-apoptotic proteins consists of Bad, Bim, Bik, Bid, Hrk, Noxa and Puma.  
They all possess the conserved BH3 domain.  These BH-3 only proteins are 
regulators rather than executioners of cell death and therefore act upstream of Bax 
and Bak proteins (Cheng et al., 2001; Zong et al., 2001).  Their activities are 
regulated either at the transcriptional level in the case of Noxa and Puma, or by 
post-translational modification as demonstrated in Bad, Bim and Bid (Strasser, 
2005). 
 In the direct method of activation, BH-3 pro-apoptotic proteins bind and 
activate Bax and Bak.  In this model, BH-3 proteins are sub-divided into two 
groups namely activators or sensitisers based on their functions (Letai et al., 
2002).  The activator proteins include tBid and Bim and the sensitiser proteins 
include Bad, Noxa and Puma.  tBid and Bim bind directly to Bax and Bak and 
activate these proteins, whereas the sensitiser proteins bind to their anti-apoptotic 
Bcl-2 protein members, liberating Bax and Bak and consequently activating Bax- 
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and Bak-induced apoptosis  (Chipuk et al., 2008; Kim et al., 2006; Walensky et 











Fig 1.8: Model depicting the direct activation of Bax and Bak (adapted from  
(Brenner and Mak, 2009)) 
 
 In the indirect activation model, Bax and Bak are kept inactive by 
sequestration mediated by binding to anti-apoptotic Bcl-2 family members (Willis 
et al., 2005; Willis et al., 2007).  The binding of BH3-only proteins to anti-
apoptotic Bcl-2 proteins releases Bax and Bak from the inhibitory action of these 
Bcl-2 proteins (Fig 1.9).  This allows for the subsequent initiation of apoptosis by 





















Fig 1.9: Model depicting the indirect activation of Bax and Bak (adapted from 
(Brenner and Mak, 2009)) 
 
 Once the inhibition of Bax is lifted, it translocates from the cytosol to the 
OMM.  Inactive Bak is found at the outer mitochondrial membrane (complex with 
Mcl-1 and Bcl-XL) (Hsu et al., 1997; Willis et al., 2005; Wolter et al., 1997).  The 
active form of Bak together with the recently translocated Bax initiates the 
disruption of the OMM leading to mitochondrial outer membrane 
permeabilisation (MOMP).  The change in MOMP leads to the release of 
cytochrome c and other pro-apoptotic proteins from the mitochondrial inter-
membrane space (IMS) into the cytosol. 
 Cytochrome c is found in the intermembrane space of the mitochondrion 
and most of them are loosely attached to the outer surface of the inner 
mitochrondrial membrane.   Besides its role in oxidation phosphorylation, 
cytochrome c is also critical in the caspase activation cascade (Liu et al., 1996).  
Upon its release from the mitochondrion, cytochrome c interacts with the 
apoptotic-activating factor-1 (Apaf-1), ATP/dATP, and caspase-9 to form the 
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apoptosome (Hao et al., 2005; Li et al., 1997b).  Apaf-1 possesses a caspase 
recruitment domain (CARD) which mediates its interaction with caspase-9, and a 
WD-40 repeat domain that maintains Apaf-1 in its inactive form in the absence of 
cytochrome c (Hu et al., 1998).  In the presence of cytochrome c and ATP/dATP, 
Apaf-1 undergoes a conformational change that leads to its aggregation consisting 
of seven Apaf-1 molecule, each bound to one molecule of cytochrome c and one 
caspase-9 (Acehan et al., 2002) and exposure of CARD for subsequent 
recruitment of the initiator caspase, procaspase-9 to it domain.  Unlike other 
caspases, procaspase-9 is not activated by proteolytic cleavage but, instead, must 
be complexed to Apaf-1 for activation (Rodriguez and Lazebnik, 1999).  The 
apoptosome recruits and activates caspase -3 and -7 by proteolytic cleavage and 
subsequent cell death in an orderly manner through controlled proteolytic 
processing of downstream target proteins (Fig 1.10). 
 Caspases are kept in the inactive state in the cytosol when they are 
complexed with specific proteins termed inhibitors of apoptosis (IAPs).  Members 
of the IAP family in human include X-linked inhibitor of apoptosis (XIAP), 
cIAP1, cIAP2, ILP2, ML-IAP, NAIP, survivin and BRUCE (BIR repeat-
containing ubiquitin-conjugating enzyme) (Srinivasula and Ashwell, 2008). These 
proteins bear one or more baculovirus IAP repeat (BIR) motifs, a sequence of 
about 70 amino acids with a RING finger zinc-binding domain at the carboxyl 
terminal of the BIR repeats (Liston et al., 1996; Vaux and Silke, 2005).  In 
addition, near the RING finger of c-IAP1 and c-IAP2 is a CARD, suggesting that 
these IAPS may directly or indirectly regulate the processing of caspases via 
CARD interactions (Hofmann et al., 1997).  IAPs complex with and inhibit active 
caspase -3 and -7 but not caspase -1, -6, -8, -10 (Deveraux et al., 1997; Roy et al., 
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1997).  This binding and inhibition is mediated by the BIR domains within the 
IAPs.  IAPs can also inhibit caspase-9 but via a different mechanism; they bind to 
inactive procaspase-9 and interfere with the processing of procaspase-9 (Deveraux 
et al., 1998; Takahashi et al., 1998).  IAPs thus put a brake on the apoptotic 
process by binding and inhibiting caspases, thereby prolonging cell survival. 
 IAPs in turn are subjected to regulation mediated by a second 
mitochondrial activator of caspases/direct IAP protein-binding protein of low pI 
(Smac/DIABLO).  These proteins are released together with cytochrome c from 
the mitochondria.  They bind to and antagonise the function of IAPs, freeing the 
caspases from the inhibitory action of these IAPs.   Smac/DIABLOs do so by 
binding to the BIR repeats on IAPs (Wu et al., 2000).  Omi/HTRA2, is also 
released together with Smac/DIABLO and cytochrome c can inactivate IAPs as 












Fig 1.10: Caspase activation by cytochrome c from a mitochondrion (adapted 
from (Budihardjo et al., 1999)) 
 
 
Page | 42  
 
 There is cooperation between the intrinsic and extrinsic apoptotic 
pathways and is mediated by the Bid protein.  This protein is cleaved by caspase-8 
(activated by the extrinsic pathway) to generate the active pro-apoptotic protein 
tBid (Fig 1.7).  tBid helps to amplify the signal induced by the death receptor 
stimulation in certain cell types (Gross et al., 1999). Activated BH3-only pro-
apoptotic proteins translocate to the outer mitochondrial membrane (OMM) and 
exert their pro-apoptotic functions.   Currently, there are two conflicting models; 
the direct and indirect methods of activation to explain how BH3-only proteins 
activate Bax and Bak. 
 
1.5 PI3K-Akt pathway 
 PI3Ks, a family of lipid kinases have key regulatory roles in many cellular 
processes which include cell survival, cell proliferation, metabolism and motility 
(Engelman et al., 2006; Hietakangas and Cohen, 2009; Kolsch et al., 2008; 
Martelli et al., 2010; Morello et al., 2009; Oudit and Penninger, 2009).  As major 
effectors downstream of receptor tyrosine kinases (RTKs) as well as the G 
protein-coupled receptors (GPCRs), PI3Ks transduce signals upon growth factors 
and cytokines binding to these receptors which result in activation of key proteins 
downstream, including the serine-threonine protein kinase Akt (also known as 
protein kinase B (PKB)) . 
 Akt was first isolated from an AKR thymonia and subsequently found to 
be an oncogene transduced by the acute transforming retrovirus (Staal, 1987).  
Since then, three members of the Akt family have been identified as Akt1, Akt2 
and Akt3; and they are also referred as PKB, PKB and PKB respectively.  
Although each of these classes of Akt is encoded by distinct gene, the three 
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proteins share more than 80% homology at the amino acid level (Datta et al., 
1999; Nicholson and Anderson, 2002).   All Akt isoforms share similar structures, 
including a pleckstrin homology (PH) domain at the amino-terminal, a central 
serine-threonine catalytic domain and a carboxyl-terminal that possesses 
regulatory domain for the induction and maintenance of its kinase activity 
(reviewed by (Chan et al., 1999)).   Activation of Akt requires two 
phosphorylation events; one at Tyr
308
 and the second at Ser
473
, catalysed by 3-
phosphoinositide-dependent protein kinase 1 (PDK1) and PDK2 respectively 
(Alessi et al., 1997; Scheid and Woodgett, 2001).  These events occur in response 
to growth factors and other extracellular stimuli (Alessi et al., 1996; Brazil et al., 
2004).  
 Akt are ubiquitously expressed, but expression levels vary depending on 
the tissue types.  The PH domain of Akt binds to phosphatidylinositol-3, 4, 5-
triphosphate (PIP3) formed from the phosphorylation of membrane phospholipid, 
phosphatidylinositol-4, 5-bisphosphate (PIP2) by PI3K (Cantley, 2002) (Fig 1.11).  
Activated Akt subsequently translocates to the cytosol and nucleus to 
phosphorylate its substrates (Arden and Biggs, 2002; Franke, 2008; Huang and 
Chen, 2005).  Activation of Akt leads to cell cycle progression, survival, 
metabolism and migration via serine / threonine phosphorylation (Dahia, 2000; 
Downward, 2004; Kandel and Hay, 1999; Vivanco and Sawyers, 2002) (Fig 1.11). 
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Fig 1.11: The phosphoinositide 3-kinase-Akt signalling cascade (adapted from  
(Tokunaga et al., 2008)) 
 
 As Akt activation is initiated by Akt binding to PIP3 which is generated 
downstream by PI3K, the cell has a regulator in the form of a tumour suppressor, 
phosphate and tensin homolog (PTEN).  The latter proteins antagonise PI3K 
activity.  PTEN possesses lipid phosphatase activity and reduces the cellular pool 
of PIP3 by dephosphorylating it to PIP2, thus negatively regulating Akt activity 
(Maehama and Dixon, 1998; Stambolic et al., 1998). 
 
1.5.1  Akt in cell survival 
 Akt is critical for cell survival as it exerts its effect by direct 
phosphorylation of transcription factors involved in pro- and anti-apoptotic gene 
expressions and pro-apoptotic proteins (Datta et al., 1999).  Akt negatively 
regulates the transcription factors that promote the expression of death genes 
encoding for the forkhead transcription factors FKHR, FKHRL1 and AFX (Biggs 
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et al., 1999; Brunet et al., 1999; Rena et al., 1999) (Fig 1.11).  It can also prevent 
apoptosis by activating  IB kinase (IKK) (Romashkova and Makarov, 1999) and 
cyclic-AMP response element-binding protein (CREB) (Du and Montminy, 1998) 
(Fig 1.11).  Akt also promotes cell survival by directly phosphorylating Bad and 
procaspase-9, key proteins in apoptosis (Datta et al., 1999) (Fig 1.11). 
 One must not overlook the effects of Akt on p53, a tumour suppressor that 
regulates cell cycle and apoptosis (Levine, 1997).  One of the substrates of Akt 
phosphorylation is MDM2, which leads to subsequent proteasomal degradation of 
p53 (Mayo and Donner, 2002; Zhou et al., 2001). By enhancing the degradation 
of p53, Akt negatively regulate apoptosis.  Akt also negatively regulate apoptosis 
through other key proteins of apoptosis like Bad.  Akt phosphorylates Bad, a pro-
apoptotic Bcl2 family member at Ser
136
 which promotes cell survival by inhibiting 
its interaction with the anti-apoptotic Bcl2 protein members like Bcl-xL and 
preventing the release of cytochrome c (Datta et al., 1997).  Akt is able to 
phosphorylate procaspase-9 at Ser
196
 resulting in a conformational change to the 
protein and inhibiting its proteolytic activity (Cardone et al., 1998).  The forkhead 
transcription factor, FKHRL1 whose target genes include FasL, Bim, IGFBP1 and 
Puma is inhibited when phosphorylated by Akt and thus prevents transcription of 
these target genes whose gene products are regulatory apoptotic proteins (Brunet 
et al., 1999; Guo et al., 1999; Kops et al., 1999; You et al., 2006).   
 Akt enhances the expression of cell survival genes like Bcl-xL, Bcl2, c-
IAPs, c-FLIP by phosphorylating and activating IKK (Kane et al., 1999; 
Romashkova and Makarov, 1999), which in turn acts on IB, freeing NF-B from 
its complex formation with IB.  NF-B is a transcription factor for these genes 
(Catz and Johnson, 2001; Lee et al., 1999; Wang et al., 1998).  Similar to the 
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indirect effects of Akt on NF-B, CREB is also affected but directly by Akt 
phosphorylation as phosphorylated CREB will up-regulate the transcription of 
pro-survival genes like Bcl2, Mcl-1 and Akt itself (Pugazhenthi et al., 2000; 
Reusch and Klemm, 2002; Wang et al., 1999). 
 
1.5.2  Akt in cell cycle progression and cell proliferation 
 PI3/Akt pathway plays a key role in the G1/S cell cycle progression (Liang 
and Slingerland, 2003) by phosphorylating key proteins involved in protein 
synthesis and cell cycle regulation.  These include glycogen synthase kinase-3 





; and the mammalian target of rapamycin (mTOR) (Fig 1.11) 
(Li et al., 2002; Liang et al., 2002; Rossig et al., 2002; Shin et al., 2002). 
 GSK-3 phosphorylates cyclin D1 and c-Myc which are key proteins in 
the G1 phase of the cell cycle (Blagosklonny and Pardee, 2002) and in the process 
promotes their degradation resulting in cell cycle arrest (Alt et al., 2000; Diehl et 
al., 1998).  Akt is able to promote cellular division by phosphorylating and 
inhibiting GSK-3, thus preventing the breakdown of cyclin D1 and c-Myc (Diehl 
et al., 1998; Takahashi-Yanaga and Sasaguri, 2008). 
 Akt also phosphorylates and inhibits the forkhead transcription factor 
which leads to enhanced cyclin D1 expression and at the same time, represses 
p27
KIP1
 and p130Rb2 expressions (Burgering and Medema, 2003; Kops et al., 





 directly; enhancing their proteasomal degradation and 
promoting cellular division (Li et al., 2002; Liang et al., 2002; Rossig et al., 2001; 
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up-regulating the expression of SKP2, a key component of the SCF/SKP2 




degradation (Bashir et al., 
2004). 
  
1.5.3  The role of Akt in translational regulation 
 Translation in cells is controlled by many factors amongst them nutrient 
availability and growth factor stimuli which are regulated by the mammalian 
target of rapamycin (mTOR) (Schmelzle and Hall, 2000). Akt phosphorylates and 
inhibits tuberous sclerosis protein 2 (TSC2), a part of the tuberous sclerosis 
complex (Pan et al., 2004).  Once phosphorylated, the complex is no longer able 
to suppress the activity of GTP-binding Rheb (Ras homology enriched in brain), a 
protein that phosphorylates and activates mTOR (Huang and Manning, 2009).  
mTOR will subsequently stimulate cell proliferation by activating the ribosomal 
protein S6 kinase (p70S6K) and inhibiting the elongation-initiation factor 4E-
binding protein (4E-BP) (Nave et al., 1999; Wendel et al., 2004).   
 
1.5.4  Activation of PI3K-Akt pathway and cancer development 
 Many human cancers exhibit excessive Akt activity and these include 
carcinoma, prostate, gastric, lung, ovary, pancreas and thyroid; glioblastoma and 
various haematological malignancies and nasopharyngeal carcinoma (Altomare 
and Testa, 2005; Carnero, 2010; Courtney et al., 2010; Liu et al., 2009; Morrison 
et al., 2004).  Studies have also demonstrated a close association between Akt 
activation and the clinicopathological characteristics such as advanced stage, poor 
prognosis and histological grade (Altomare and Testa, 2005).   
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 Akt activation in human cancer is caused by various mechanisms ranging 
from alteration of PI3K expression and activity (Bertelsen et al., 2006; Kadota et 
al., 2009; Murugan et al., 2008); Akt amplification and over-expression (Carpten 
et al., 2007; Davies et al., 2008; Pedrero et al., 2005) and down-regulation of 
PTEN via gene mutation, deletion or promoter methylation (Byun et al., 2003; Li 





 It has been estimated that 75 – 85% of all chronic illnesses and diseases 
are associated with lifestyle and cannot be explained by differences in genetic 
makeup alone (Wong et al., 2005).  Studies have indicated a strong linkage 
between fat and red meat and the development of colorectal adenomas and at the 
same time, an inverse association between dietary fibres, fruit and vegetable 
intake with this disease  (Mathew et al., 2004; Robertson et al., 2005).  Moreover, 
epidemiological studies have demonstrated that consumption of food rich in fruits 
and vegetables results in low incidence of cancers (Block et al., 1992; Key et al., 
2004; Linos and Willett, 2007; Reddy et al., 2003; Willett, 2000).  A review of 
206 human epidemiological studies and 22 animal studies conducted by Steinmetz 
& Potter demonstrated an inverse relationship between consumption of fruits and 
vegetables; and the risk of developing cancers of the stomach, oesophagus, lung, 
oral cavity pharynx, endometrium, pancreas and colon  (Steinmetz and Potter, 
1996). 
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 Although it is not clear which components in fruits and vegetables are 
responsible for this preventive anti-cancer property, evidences point towards the 
presence of fibres, vitamins, minerals, polyphenols, terpenes, alkaloids and 
phenolics in fruits and vegetables as the contributing factors. These dietary agents 
can suppress the inflammatory processes that lead to transformation, proliferation 
and initiation of carcinogenesis. 
 Flavonoids comprise the most common group of plant polyphenols and 
provide much of the flavour and colour to fruits and vegetables.  In plants, these 
polyphenolic compounds are critical in plant physiology.  They are involved in 
plant growth and reproduction, provide resistance to plant pathogens and 
predators, protection against diseases and pre-harvest seed germination (Bravo, 
1998).  When consumed in our daily diet, flavonoids have been found to exert 
beneficial effects like anti-oxidative (Burda and Oleszek, 2001), anti-viral (Guo et 
al., 2007; Liu et al., 2008; Roschek et al., 2009), anti-tumour (Cardenas et al., 
2006), anti-inflammatory (Gonzalez-Gallego et al., 2007; Tunon et al., 2009).  
They are also able to prevent cardiovascular diseases (Tijburg et al., 1997) and 
exhibit hepato-protective activities (Yao et al., 2007). 
 
1.6.2 Structures of flavonoids and their bioavailability 
 Flavonoids have a common diphenylpropane structure (C6-C3-C6) 
consisting of two aromatic rings joined by a three-carbon cyclic ring (Fig 1.12).  
Based on the variation to the heterocyclic C-ring, flavonoids are sub-divided into 
six major sub-classes.  They include flavones, flavonols, flavonones, catechins, 
anthocyanidins and isoflavones (Fig 1.13).  There are over 4000 naturally 
occurring flavonoids. 












Fig 1.13: Chemical structures of the six major sub-classes of flavonoids 
(adapted from (Ross and Kasum, 2002)) 
 
 Flavonoids present in human diet are mainly in the glycoside form.  The 
biological fate of dietary flavonoid glycosides has always been an elusive and 
controversial issue.  Some reports have demonstrated that the flavonoid 
glycosides cannot be absorbed in this form but need to be hydrolysed to their 
aglycone by bacterial enzymes in the lower part of the intestine before being 
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partially absorbed or may undergo further bio-transformation by bacteria 
(Bokkenheuser et al., 1987).  This was further verified by studies with quercetin 
glycosides which indicated that they were not absorbed intact in humans and 
therefore not found in the systemic circulation (Erlund et al., 2000; Mullen et al., 
2006).  Similar findings have also been made with the glycosides of diosmetin 
(Cova et al., 1992), isoflavones (Williamson et al., 2005) and luteolin (Shimoi et 
al., 1998). 
 
1.6.3 Anti-oxidant activity of flavonoids 
 The beneficial effects of flavonoids in chemopreventive therapy have been 
linked to their anti-oxidant activity which includes their redox potential and 
reactive oxygen species (ROS) –scavenging capabilities (Duthie and Crozier, 
2000).  Contrary to general belief, recent studies showed flavonoids exerting their 
anti-oxidant role through their effects on protein kinase and lipid kinase signalling 
pathways and not as conventional hydrogen-donating anti-oxidants (Williams et 
al., 2004).  Although flavonoids exhibit anti-oxidant activity, however they are 
not likely to act as major anti-oxidants in vivo as endogenous anti-oxidants like 
ascorbic acids are present at a higher concentration in the body and therefore will 
be the major player as anti-oxidant instead.  Flavonoid concentrations in vivo 
however may be high enough to mediate receptor or enzyme activity leading to 
the inhibition or up-regulation of various signalling pathways like tyrosine 
kinases, protein kinase C and mitogen-activated protein kinase. 
 Although the chemopreventive properties of flavonoids are linked with 
their ability to scavenge endogenous ROS, however new studies have emerged 
suggesting that these dietary agents may protect free-radical-induced damage to 
Page | 52  
 
DNA by a mechanism other than direct free-radical scavenging.  Flavonoids can 
reduce the incidence of single-strand breaks in double-stranded DNA as well as 
residual base damage through fast chemical repair (Anderson et al., 2000).   
 There are also reports indicating flavonoids as pro-oxidative in their action 
and it may be this action which gives rise to the anti-cancer property of flavonoids 
instead of their anti-oxidant activity (Hadi et al., 2000; Rahman et al., 1990).  
Some anti-cancer agents cause apoptotic DNA fragmentation mediated by ROS 
(Kaufmann, 1989).  Certain dietary phenolic compounds like quercetin can also 
bind and cleave DNA and at the same time generate ROS in the presence of 
transition metal ions  like copper (Rahman et al., 1990);  a mechanism similar to 
those of known anti-cancer drugs. 
 A second mechanism for the anti-cancer and tumour cell apoptosis-
inducing properties of flavonoids based on their pro-oxidant activity is their 
effects on mitochondria.  Certain flavonoids have been demonstrated to cause the 
collapse of the mitochondrial membrane potential causing apoptosis in tumour 
cells (Chung et al., 2001; Morin et al., 2001; Surh et al., 1999). 
 
1.6.4 Anti-oestrogenic (and oestrogenic) activity of flavonoids 
 Exposure to both endogenous and exogenous oestrogens has been 
associated with an increased risk factor for some hormone-dependent cancers like 
breast cancers.  Phyto-oestrogens are phenolic non-steroidal plant compounds 
with oestrogen-like biological activity.  Isoflavones like genistein and other 
flavonoids like apigenin, kaempferol and resveratrol exhibit both anti-oestrogenic 
as well as oestrogenic activities associated with oestrogen-receptor binding (Cos 
et al., 2003).  There are evidences to demonstrate that in countries where the 
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average intake of phyto-oestrogens is higher compared to some other countries, 
there is lower incidence rate of cancers associated with oestrogen exposure such 
as breast and prostate cancers (Jian, 2009; Messina and Hilakivi-Clarke, 2009; 
Perabo et al., 2008). 
 
1.6.5 Anti-tumour property of flavonoids 
 Tumourigenesis is a multi-step and multi-factorial event.  It can be 
triggered off by environmental pollutants like cigarette smoke, industrial 
emissions, petroleum vapours, inflammatory agents and tumour promoter 
chemicals like phorbol esters.  These chemicals are known to modulate 
transcription factors involved in cell survival and cell division like NF-B, AP-1   
(activator protein-1), STAT3 (signal transducer and activator of transcription 3), 
anti-apoptotic proteins like Akt, Bcl-2 and Bcl-XL; pro-apoptotic proteins like the 
caspases and PARP;  protein kinases like IKK, EGFR (epidermal growth factor 
receptor), HER2 (human epidermal growth factor receptor 2), JNK (Jun N-
terminal kinase) and MAPK;  cell cycle proteins like cyclins and their associated 
cdks;  cell adhesion molecules, COX-2A and growth factors (reviewed by  
(Aggarwal and Shishodia, 2006; Pan and Ho, 2008). 
 
1.6.5.1 Effects of flavonoids on NF-B 
 NF-B is a transcription factor that translocates to the nucleus and induces 
the transcription of over 200 genes that suppress apoptosis and induce cellular 
transformation, proliferation, invasion, metastasis and inflammation (Luqman and 
Pezzuto, 2010).  Many of these genes whose proteins play key roles in the 
establishment of early and late stage of aggressive cancers include cyclin D1, Bcl-
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2, Bcl-XL, matrix metalloproteases (MMP) and vascular endothelial growth factor 
(VGEF). 
 Numerous flavonoids have been identified to inhibit NF-B activity and 
these include curcumin (Mackenzie et al., 2008; Singh and Aggarwal, 1995), 
diosgenin (Shishodia and Aggarwal, 2006), ellagic acid (Edderkaoui et al., 2008) , 
emodin (Kumar et al., 1998), gingerol (Ishiguro et al., 2007),  epigallocatechin-2-
gallate (EGCG) (Yang et al., 2001a), luteolin (Kim and Jobin, 2005), lycopene 
(Kim et al., 2004), chrysin (Li et al., 2010b) and resveratrol (Roy et al., 2009).  
These dietary agents inhibit the NF-B pathway in one or more ways such as 
inhibiting the activation of NF-B, translocation of this transcription factor to the 
nucleus, binding to the DNA and interactions with the machinery of DNA 
transcription.    
 Thus by inhibiting one or more steps in the NF-B pathway which is a 
critical pathway in ensuring cell survival and growth, flavonoids are able to act as 
natural anti-cancer agents.   
 
1.6.5.2 Effects of flavonoids on cell cycle 
 Cell cycle progression is a very tightly controlled and highly regulated 
process in a cell (reviewed in Chapter 1.3 of this thesis); and loss of this control 
and regulation lead to cancer.  Critical proteins to control cells in G1, S, G2 and 
M phases are activated at each phase to ensure a smooth transition of cells through 
the phases.  Accumulation of ribosomes, the translational machinery in G1 phase 
is also a key event in cell growth and this involves the protein S6 kinase (S6K).  
Negative and positive regulators of S6K play a key role in determining the level 
of ribosomal S6 protein and thereby the ribosomal pool (Thomas, 2000).  S6K can 
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be activated by mitogenic stimulation in the form of EGFR and IGFR (insulin-like 
growth factor receptor) and the Ras/ERK (extracellular signal regulated kinase) 
well as the PI3K/Akt signal transduction machinery.  These will lead to down-
stream activation of proteins involved in cell division including cyclin D1 and c-
Myc  (Malumbres and Barbacid, 2001; Thomas, 2000).  Many flavonoids are able 
to inhibit the EGFR and IGFR mitogenic signalling at the receptor level in 
numerous cancer cell lines, leading to cell growth inhibition and proliferation 
(Aggarwal, 2000; Lin et al., 1999; Zi and Agarwal, 1999). 
 Cancer development can occur when there is aberration to the G1/S 
checkpoint resulting in the deregulation of the cell cycle.  Key proteins include the 
cyclins and their associated cdks; and the CKIs.  Several dietary agents like 
curcumin (Mukhopadhyay et al., 2002), resveratrol (Estrov et al., 2003), genistein 
(Li et al., 2005), apigenin (Takagaki et al., 2005) and silibinin (Tyagi et al., 2002) 
are able to reverse the deregulation of cell cycle in cancer cell lines, causing cell 
growth arrest and apoptosis. 
 The Rb family proteins play central role in cell cycle progression as they 
are the prime targets for phosphorylation by the activated cdk-cyclin complexes.  
Upon phosphorylation, pRbs release E2Fs which are transcription factors of genes 
necessary for cell cycle progression through the G1 and S phases.   There is also 
evidence that demonstrates pRb’s role in repressing gene expression, in part 
mediated by chromatin condensation and thus inhibiting gene transcription 
downstream (Harbour and Dean, 2000a).  Silibinin has been reported to increase 
the total as well as under-phosphorylated form of pRb in human prostate 
carcinoma LNCaP cells.  Cyclin D1 is over-expressed in numerous cancers.  
Curcumin is able to inhibit cell cycle progression by down-regulating the 
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transcriptional and post-translational expression of cyclin D1 (Bharti et al., 2003; 
Mukhopadhyay et al., 2002).  Numerous studies have demonstrated that different 
flavonoids regulate critical proteins in the cell cycle of cancer cell lines and 
mediate cell cycle arrest at either G1/S or G2/M.  Thus these dietary agents are 
potential candidates for cancer management in the form of chemo-preventive 
therapy in cancer patients after conventional cancer treatment.    
 
1.6.5.3 Effects of flavonoids on Akt 
 Akt is critical in mammalian cell survival and many cancer cell lines 
possess abnormal activated level of Akt (review in Chapter 1.5 of this thesis).  
Studies have identified several phytochemicals that are able to suppress the 
activation of Akt directly or via other critical proteins upstream of Akt (Fig 1.11).  
These include genistein (Li and Sarkar, 2002), indole-3-carbinol (Chinni and 
Sarkar, 2002), diosgenin (Shishodia and Aggarwal, 2006) and EGCG (Tang et al., 
2003).  Some flavonoids like curcumin (Aggarwal et al., 2006) and luteolin (Ong 
et al., 2010b) are also able to inactivate Akt. 
 These studies provide evidence of one of many molecular mechanisms of 
flavonoids as anti-cancer chemicals to suppress tumourigenesis. 
 
1.6.5.4 Effects of flavonoids on tumour suppressor p53 
 p53 a tumour-suppressor and transcription factor, is a key protein in 
regulating many cellular processes such as the cellular response to DNA damage, 
genomic stability during cell cycle, cell cycle control and apoptosis.  Lack of p53  
favours the development of cancer (Chène, 2003).  Moreover, half of the human 
cancer carries the mutated form of p53 and this is associated with poor prognosis 
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(Chène, 2003; Taylor and Stark, 2001).  Activated p53 consequently leads to the 
up-regulation of CKI, p21
CIP1 
and pro-apoptotic proteins like Bad and Bax; 
resulting in cell cycle arrest and apoptosis.  Flavonoids like curcumin (Han et al., 
1999), resveratrol (Huang et al., 1999), EGCG (Gupta et al., 2000), silibinin 
(Katiyar et al., 2005), quercetin (Ong et al., 2004) and luteolin (Shi et al., 2007) 
can modulate p53 activity, leading to cell cycle arrest and apoptosis. 
 
1.6.5.5 Activation of apoptosis by flavonoids 
 Cell cycle arrest is one of the important events in sensitising cells to 
apoptosis.  Numerous reports have demonstrated that flavonoids such as EGCG, 
genistein, quercetin, luteolin and silibinin lead to apoptosis which is a downstream 
event associated with G1 or G2/M cell cycle arrest in different types of cancers.  
In addition, stress signals elicited by flavonoids can also trigger apoptosis via NF-
B, AP-1, Bcl-2 and Bcl-XL (de Kok et al., 2008; Nishino et al., 2007; Ramos, 
2008; Thomasset et al., 2007) (Fig 1.14).  Apoptosis can be mediated by either an 
extrinsic signal between death receptors and their ligands or intrinsic signal via 
mitochondrial induced pathway.  Many flavonoids trigger apoptosis in different 
cancers through the mitochondrial-mediated pathway including retinoic acid 
(Noy, 2010), curcumin (Pesakhov et al., 2010), EGCG (Lee et al., 2010b), 
apigenin (Lu et al., 2010) , quercetin (Ong et al., 2004; Suh et al., 2010), chrysin 
(Li and Sarkar, 2002), silibinin (Pesakhov et al., 2010), silymarin (Ramakrishnan 
















Fig 1.14: Induction of apoptosis by dietary flavonoids (adapted from (Guo et 
al., 2009)) 
  
 A second potential target site of flavonoids that will result in apoptosis of 
cancer cells is the inhibition of the growth factor-mediated PI3K-Akt pathway 
(Liang et al., 1997).  There are numerous reports that demonstrate flavonoids 
mediated apoptosis of cancer cells via this pathway (Adams et al., 2010; Lin et al., 
2008; Sun et al., 2010). 
 These studies provide evidence that flavonoids act on cancer cells by 
exerting their effects on multiple signalling pathways in cells. 
 
1.7 Quercetin 
 Quercetin (3,3,4,5,7-pentahydroxylflavone) is a flavonol-type flavonoid 
ubiquitously present in plant-derived foods.  It is found in a variety of fruits like 
red onions, grapes, apples, berries, cherries, broccoli, citrus fruits and tea.  
Average daily uptake of quercetin in a human diet varies between 10 – 100 mg 
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depending on eating habits (Erlund et al., 2000).  Quercetin is commonly found as 
ortho-glycosides in which at least one hydroxyl group is substituted by various 
types of sugars (Fig 1.15).  The sugar group can be attached to C3, giving rise to 
its glycoside derivatives like quercitrin, isoquercitrin, hyperoside and rutin (Fig 
1.15).  Alternatively, the sugar group can also be bound to C4 of the parent 
quercetin chain generating quercetin-4-O--D-glucoside and quercetin-3,4-O--
D-glucoside.   Their water-solubility property increases with increasing number of 
sugar groups.  Quercetin exhibits anti-oxidant activity due to its electron-donating 
property which can be attributed to the presence of a phenolic hydroxyl group on 







Fig 1.15: Chemical structure of quercetin and its glycosides (adapted from 
(Murakami et al., 2008)) 
 
 Studies have provided evidence to indicate that dietary quercetin can be 
absorbed from the digestive tract and subsequently undergoes metabolic 
conversion (Murota et al., 2000).  Quercetin glycosides are absorbed in the small 
intestine as quercetin aglycone following hydrolysis by lactose phorizin hydrolase 
(LPH) in the brush border membranes (Walle et al., 2000) of cells in the small 
intestines.  Once quercetin is absorbed by the intestinal epithelium as aglycone 
derivative and subsequently entered the blood stream, it can be glucorinated, 
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methylated or sulphated and then bound to transport proteins.  The plasma 
protein-bound quercetin glucoronides enter tissues and this is then followed by the 
separation of the quercetin aglycone from the plasma protein inside cells (O'Leary 
et al., 2003; Spencer et al., 2003). 
 Many biological effects of quercetin on cells and tissues have been 
reported (reviewed by (Bischoff, 2008)).  Of interest in this thesis is its anti-
cancer property.  There are numerous reports to demonstrate the effects of 
quercetin on signal transductions associated with tumourigenesis and these 
include cell cycle regulation, apoptosis, pro-inflammatory protein induction and 
angiogenesis (Hirpara et al., 2009; Murakami et al., 2008).  In our study, quercetin 
was able to inhibit cell growth of nasopharyngeal carcinoma cells by inhibiting 
cell cycle progression to S phase mediated by the inhibition of  E2F function; and 
apoptosis (Ong et al., 2004). 
 
1.8 Luteolin 
 Luteolin (3,4,5,7-tetrahydroxylflavone) is a flavonol-type flavonoid 
ubiquitously present in plant-derived foods.    Luteolin-rich vegetables and fruits 
include celery, parsley, broccoli, onion leaves, carrots, peppers, cabbages, apple 
skins and chrysanthemum flowers (Miean and Mohamed, 2001; Sun et al., 2007; 
Xie et al., 2009).  In these vegetables and fruits, luteolin is present as aglycone 
(without sugar moiety) and glycosides (aglycone with one or more sugar moieties) 
(Fig 1.16).  Like quercetin, luteolin is hydrolysed to its aglycone form before 
being absorbed by the intestinal epithelium  (Shimoi et al., 1998). 
 
 












Fig 1.16: Chemical structures of luteolin and its glycosides (adapted from 
(Lopez-Lazaro, 2009)) 
 
 Luteolin exhibits a wide range of biological activities in the prevention and 
treatment of chronic diseases due to their anti-oxidant, anti-inflammatory, anti-
microbial  and anti-cancer activities (reviewed by (Lopez-Lazaro, 2009).  Of 
particular interest in this thesis is the anti-cancer property of luteolin.  In our 
laboratory, luteolin has been found to enhance TNF--induced apoptosis in 
human cell lines like colorectal cancer COLO205, HCT116; and cervical cancer 
Hela cells via suppression of NF-B (Shi et al., 2004).  In a second study, pre-
treatment of TRAIL-sensitive cancer cells like Hela and TRAIL-resistant cancer 
cells such as CNE1, HT29 and Hep G2 with a non-cytotoxic concentration of 
luteolin was able to enhance TRAIL-induced apoptosis mediated by caspase -8 
and -3 activation (Shi et al., 2005).  In a separate study, we have also 
demonstrated that luteolin was able to induce G1 cell cycle arrest in 
nasopharyngeal carcinoma cells and this was brought about by the suppression of 
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Akt activity that led to the proteasomal degradation of cyclin D1 and subsequently 
inhibition of E2F, a transcription factor critical in the cell progression from G1 to 
S phase (Ong et al., 2010a).  This last study will be elaborated under Chapter 3 of 
this thesis. 
 
1.9 Objective of this study 
 Flavonoids as chemo-preventive chemicals provide an attractive and viable 
form of cancer management as they are able to inhibit tumourigenesis via signal 
transduction involved in cell survival, cell growth and cell death.  To achieve its 
role in chemo-prevention, molecular actions of these flavonoids alone and in 
combinations on different cancer types must be elucidated to enhance efficacy and 
reduced toxicity.  A clear understanding in this area will definitely provide a 
platform for future development of flavonoids in cancer management as well as in 
other diseases such as cardiovascular, inflammatory and neurological diseases.  
Moreover, it will also elevate our understanding of the overall health benefit of 
flavonoids which are consumed in our human diet. 
 Thus, the objectives of this study are:  
1. To investigate the effect of quercetin on the cell growth inhibition and 
apoptosis of nasopharyngeal carcinoma cells and 
2. To examine the effect of luteolin on cell cycle arrest on the same type of 
cancer; and 
3. To examine the sensitisation effect of luteolin and quercetin on apoptosis 
induced by cancer chemotherapeutics. 
 










Quercetin-induced growth inhibition 
and cell death in nasopharyngeal 
carcinoma cells are associated with 
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2.1 Introduction 
 Nasopharyngeal carcinoma (NPC) is a malignancy of epithelial origin 
occurring with a high incidence rate in Southern China and South-East Asia.  In 
Southern China, it is the third most common form of malignancy amongst men, 
with incidence rate between 15 and 50 per 100, 000 (Ho, 1978).  In Singapore, the 
incidence rates are 18.4 per 100 000 in males and 7.3 per 100,000 in females 
(Chia et al., 1996).  Independent studies by Serin et al (Serin et al., 1999), Cheng 
et al (Cheng et al., 2000) and Wei and Kwong (Wei and Kwong, 2010) have 
demonstrated that the combination of radiotherapy and chemotherapy in both 
early and late stage cases have helped to improve the prognosis of NPC patients.  
Patients were treated with cisplatin  (Serin et al., 1999) and cis-diamine-
dichloroplatinum and fluorouracil (Cheng et al., 2000) in addition to radiotherapy, 
and they exhibited improved prognosis.  However toxicities were observed in 
some patients after chemotherapy which included mucositis (Wong et al., 2006), 
grade III/IV neutropenia (Chua et al., 2004; McCarthy et al., 2002), grade III/IV 
anaemia, granulocytopenia and thrombocytopenia (Leong et al., 2005; Ngan et al., 
2002).  The use of  flavonoids with anti-tumour property to control cancer growth 
may help to circumvent some of these toxicities experienced by patients as these 
are found in fruits and vegetables; and are consumed in our daily diet.   
 Humans ingest about 1 g of flavonoids daily in their diet (Scalbert and 
Williamson, 2000).  The most common flavonoid aglycones found in the diet are 
quercetin, rutin and robinin (Kuhnau, 1976).  Quercitrin and rutin are hydrolysed 
to quercetin by obligate anaerobes in the gastrointestinal tract (Bokkenheuser et 
al., 1987).  Quercetin is also widely distributed in the edible portion of most 
dietary plants like citrus fruits, berries, leafy vegetables, roots, tubers and bulbs; 
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and legumes.  These flavonoids are increasingly been associated with 
cytoprotective anti-tumour properties against cancers in various animal models 
(Steinmetz and Potter, 1996).  The molecular actions responsible for these effects 
have not been fully elucidated but may involve interaction with xenobiotic 
metabolising enzymes that are capable of altering the metabolic activation of 
potential carcinogens (Eaton et al., 1996; Obermeier et al., 1995; Polyak et al., 
2010; Siess et al., 1989).  Quercetin has been found to inhibit growth of human 
cancers like leukaemia (Kang and Liang, 1997; Russo et al., 2010), breast 
carcinoma (Chien et al., 2009; Choi et al., 2008; Choi et al., 2001), colon 
adenocarcinoma (Murtaza et al., 2006; Salucci et al., 2002), prostate cancer 
(Aalinkeel et al., 2008; Jung et al., 2010) and endometrial cancer (Kaneuchi et al., 
2003).  It can inhibit the growth of malignant tumour cells through various 
molecular actions which include cell cycle arrest (Choi et al., 2001; Kaneuchi et 
al., 2003; Salucci et al., 2002), and apoptosis (Chien et al., 2009; Choi et al., 2001; 
Iwao and Tsukamoto, 1999).  However, the exact mechanism that leads to cell 
cycle and/or apoptosis in most cancers remains unclear. 
 Although quercetin exhibits anti-proliferative effects in numerous cancers 
(Chien et al., 2009; Choi et al., 2008; Jung et al., 2010; Kang and Liang, 1997; 
Russo et al., 2010), there is no report on its anti-proliferative activity on NPC.  In 
this study, we demonstrate that two NPC lines, CNE2 and HK1 exhibit different 
degree of susceptibility to quercetin; with CNE2 cells less susceptible to the 
cytotoxic effect of quercetin compared to HK1 cells.  Quercetin induced growth 
inhibition in these cells by entrapping cells in the G2/M and G0/G1 phases and 
hence preventing cell cycle progression to the S phase.  It also induced cell death 
through apoptosis and necrosis. 
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2.2 Materials and methods 
 
2.2.1 Chemicals and reagents 
 Dimethyl sulphoxide (DMSO), Igepal CA-630, quercetin, antibiotics (50 
U/ml penicillin and 50 g/ml streptomycin), Triton X-100 and trypsin-EDTA 
(ethylenediaminetetraacetic acid) (0.25% trypsin and 6.8 mM EDTA) were 
purchased from Sigma-Aldrich Company (St. Louis, MO, USA).  Quercetin was 
dissolved in DMSO at a concentration of 296 mM (50.0 mg/ml) stock.  RPMI-
1640 and foetal bovine serum (FBS) were purchased from Gibco Ltd. (Grand 
Island, NY, USA).  Reagents used for Western blot analysis were purchased from 
Bio-Rad (Hercules, CA, USA).  Protease inhibitor cocktail was purchased from 
Roche Diagnostics (Mannheim, Germany).  Rabbit anti-Bad, rabbit anti-cleaved 
caspase-3, rabbit anti-cleaved caspase-7, rabbit anti-PARP, rabbit anti-cleaved 
PARP, rabbit anti-phosphorylated-p53 (Ser
9
) antibodies, horseradish peroxidise-
conjugated goat anti-rabbit and goat anti-mouse secondary antibodies were 
purchased from Cell Signaling Technology (Beverly, MA, USA).  Mouse anti-
Bax, mouse anti-p53, mouse anti-p21
CIP1
 and mouse anti--tubulin antibodies 
were purchased from Neomarkers Inc (Fremont, CA, USA).  Mouse anti-Rb and 
mouse anti-hypophosphorylated Rb antibodies were purchased from Becton-
Dickinson (BD) Pharmingen (Palo Alto, CA, USA). 
 
2.2.2 Cell lines and cell culture 
 CNE2, a poorly differentiated line from a 68-year –old Chinese male 
(Sizhong et al., 1983) and HK1, a well differentiated NPC line from a Chinese 
male (Huang et al., 1980) were kindly provided by Professor KM Hui, National 
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Cancer Centre, Singapore.  They were grown and maintained at 37
o
C in a 
humidified 5% CO2 and 95% air atmosphere in RPMI-1640 medium, 
supplemented with 10% FBS and antibiotics.  Cells for experiments were 
trypsinised in trypsin-EDTA. 
 
2.2.3 Proliferation assay 
 Cell inhibition/proliferation assays were carried out by seeding cells 
between 0.5 – 1.0 x 104 cells to each well of 96-well microtitre plates and 
incubated overnight to allow for cell adherence.  This was followed by adding 
quercetin at 14.8 (5.0 g/ml), 29.6 (10.0 g/ml) and 59.2 (20.0 g/ml) M in 
serum-free RPMI-1640 medium to the cells and incubating for 24 and 48 h.  The 
incorporation of bromodeoxyuridine (BrdU) and subsequent enzyme linked 
immunosorbent assay (ELISA) were carried out as specified by the manufacturer 
(Roche Molecular Biochemicals, Mannheim, Germany).  All results were 
presented as means  standard error from four independent experiments, each 
measured in quadruple. 
 
2.2.4 Cell cycle and apoptosis analysis assays 
 Cell cycle analysis of DNA content was performed using propidium iodide 
(PI) provided in the cell cycle test kit (BD Biosciences, Palo Alto, CA, USA).  
Briefly, cells were grown in 100 mm dishes until 70% confluence before being 
treated with 14.8, 29.6 and 59.2 M quercetin in serum-free RPMI-1640 medium 
for 24 and 48 h.  Treated cells were trypsinised, harvested and subjected to 
treatment as described by the manufacturer.  Apoptosis in untreated and quercetin 
treated cells were determined by using the Annexin V-FITC (fluorescein 
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isothiocyanate) apoptosis detection kit (BD Biosciences, Palo Alto, CA, USA) 
and the data analysed using the FACSort flow cytometer (BD). 
 
2.2.5 Protein extraction and western blot analysis 
 Cells were lysed in lysis buffer (1% Triton X-100, 0.3 M NaCl, 20 mM 
Tris pH 7.4, 2 mM EDTA, 0.5 mM sodium vanadate, 1% Igepal CA-630 and 
protease inhibitor cocktail).  The extracted cellular proteins were subjected to gel 
electrophoresis at 100.0 g/ml and western blot analysis as previously described 
(Huynh et al., 1995).  Blots were incubated with indicated primary antibodies (all 
the antibodies were used at a final concentration of 1.0 g/ml) and horseradish 
peroxidise-conjugated goat anti-rabbit or goat anti-mouse secondary antibody 
(1:1500).  Blots were visualised with a chemiluminescent detection system as 
described by the manufacturer (Perkin Elmer, Boston, MA, USA). 
 
2.3 Results and discussion 
 
2.3.1 Quercetin inhibits the growth of CNE2 and HK1 cells 
 The growth inhibitory effect of quercetin on CNE2 and HK1 cells were 
examined by exposing these cells to different concentrations of quercetin ranging 
from 14.8 – 59.2 M, for 24 h.  The effect on cell growth was monitored by BrdU 
incorporation and subsequently quantified by ELISA.  Growth of these cells was 
inhibited by quercetin in a dose-dependent manner (Fig 2.1).  By applying linear 
progression on Fig 2.1, IC50 (inhibitory concentration resulting in 50% inhibition 
of cell growth) at 24 h were estimated to be 35.0 and 54.5 M for HK1 and CNE2 
Page | 70  
 
cells respectively.   This demonstrates that HK1 cells were more susceptible than 
CNE2 cells to the anti-proliferative activity of quercetin.   
 
Fig 2.1: Survival curves of quercetin treated CNE2 and HK1 cells  
CNE2 (5.0 x 10
3
/well) and HK1 (1.0 x 10
4
 /well) were plated in 96-well microtitre plates in RPMI-
1640 medium supplemented with 10% FBS overnight.  Cells were treated with 0, 14.8, 29.6 and 
59.2 M of quercetin in serum-free RPMI-1640 medium for 24 h. Cell proliferation was 
determined by the amount of BrdU incorporated into the cells.  These values were expressed in 
percentage with untreated cells as 100%.  All results were presented as means   standard error 
from four independent experiments, each measured in quadruple.  By applying linear regression on 
the graph, IC50 for CNE2 and HK1 were subsequently determined. 
 
 A possible reason to explain the different susceptibility of CNE2 and HK1 
cells to quercetin could be attributed to an increase in Bad and Bax protein levels 
in quercetin treated HK1 as demonstrated by Western blot analysis (Fig 2.6 F and 
G).  Bad and Bax proteins reside in the cytosol but translocate to the mitochondria 
following death signalling, thereby promoting the release of cytochrome c.  The 
consequence of this activity is cell death by apoptosis.  Hence cell death of HK1 
cells by apoptosis was triggered by the increase in Bad and Bax.  In CNE2 cells, 
quercetin treatment led to an increase in Bad but not Bax expression (Fig 2.5 F 
and G).  The increase level of both pro-apoptotic proteins Bad and Bax in 
quercetin treated HK1 cells compared to only Bad increase in quercetin treated 
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CNE2 could have made the former more susceptible to quercetin compared to the 
latter.   This was verified by a lower IC50 value observed in quercetin treated 
CNE2 cells compared to HK1.  A possible explanation could be linked to the type 
of p53 expressed by these cells.  HK1 cells express wild-type p53 whereas CNE2 
cells express the mutant form of p53.  Since p53 is a transcription factor for Bax, 
the different form of p53 may play a critical role in the level of Bax expression.  
This would need further verification.  The mutant form of p53 in CNE2 cells may 
cause the cells to be less responsive to quercetin treatment compared to the wild-
type bearing p53 HK1 cells, thus making CNE2 cells more resistant to the anti-
proliferative activity of quercetin compared to HK1 cells. 
 
2.3.2 Cell cycle arrest at G2/M and G0/G1 phases in quercetin treated 
CNE2 and HK1 cells 
 
 Treating CNE2 and HK1 cells with 14.8 M quercetin for 24 h markedly 
increased the accumulation of cells in the G2/M phase equivalent to 36.9% and 
31.3% of their cell population respectively (Fig 2.2).  However, in the presence of 
higher doses of quercetin, there was a shift in the cell cycle pattern.  At 29.6 M 
of quercetin, 56.4% of CNE2 and 44.8% of HK1 cell populations were in the 
G0/G1 phase (Fig 2.2 C and G).  A similar cell cycle profile was also observed 
when both cell lines were exposed to quercetin for 48 h (data not shown).  Since 
p53 and pRb have been found to regulate cell cycle progression, we next 
examined the expression of the two proteins by western blot analysis.  As 
demonstrated in Fig 2.3 A and B, expression of p53 and the phosphorylated form 
of p53 Ser
9 
were not significantly increased by treatment with quercetin, hence it 
is unlikely that p53 was involved in cell cycle regulation following this treatment.  
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 were also 
performed but did not yield any band (data not shown).  The expression of the  
hypophosphorylated form of pRb however was significantly increased in a dose-
dependent manner from 1.0-fold in untreated CNE2 cells to 3.2-fold when these 
cells were treated with 29.6 M quercetin for 24 h (Fig 2.3).  Similarly in HK1 
cells, the amount of hypophosphorylated form also increased from 1.0-fold for 
untreated cells to 2.6-fold when they were exposed to 29.6 M of quercetin for 24 
h (Fig 2.3A).  The increase in total pRb in quercetin treated CNE2 cells was more 
significant, ranging from 2.0- to 3.5- fold increase compared to the untreated cells 
(Fig 2.3B), with most of the proteins existing as the hypophosphorylated form.  
This helped to explain the cell cycle arrest of CNE2 and HK1 cells by quercetin as 
the hypophosphorylated form of Rb blocks the activity of the E2F-1 family of 
transcription factors, consequently preventing cells from entering the S phase.  
  This argument is supported by our flow cytometry data which 
demonstrated that quercetin treated HK1 and CNE2 cells were all trapped in either 
the G2/M or G/G1 phase (Fig 2.2) 
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Fig 2.2: Cell analysis of quercetin treated and untreated CNE2 (A-D) and 
HK1 (E-H) cells 
Actively dividing cells were incubated with quercetin in serum-free RPMI-1640 medium at 0, 
14.8, 29.6 and 59.2 M for 24 h, followed by flow cytometry analysing PI.  The data were 
analysed as described in Materials and Methods. 
  
























Fig 2.3: Quercetin up-regulates pRb and underphospho form of Rb in NPC 
cells  
(A) CNE2 cells were treated with different concentrations of quercetin for 24 and 48 h.  Total 
cellular protein extracts were prepared and subjected to immunoblotting.  (B) HK1 cells were 
treated as in (A) and the total cellular protein extracts were prepared and subjected to 
immunoblotting.  Band intensity was quantified using the Bio-Rad Quantity-One programme and 
normalised against -tubulin.  The fold change/difference was computed against the intensity of 
the band obtained from untreated cells at 24 h. 
 
 
Page | 75  
 
2.3.3 Induction of cell death via apoptosis and necrosis in quercetin 
treated cells 
 
 We next examined the cytotoxic activity of quercetin on CNE2 and HK1 
cells.  Data from Figs 2.4 and 2.5 demonstrated that quercetin was able to induce 
apoptosis in both cell lines in a dose- and time-dependent manner.  Taking into 
consideration the basal level of apoptosis seen in untreated HK1 cells, at 14.8 M, 
quercetin was able to induce 6.42% of the cell population to undergo apoptosis at 
24 h incubation and almost quadrupled to 24.34% with prolonged incubation up to 
48 h demonstrating the apoptotic effect of quercetin on HK1 cells in a time 
dependent manner.  When quercetin concentration was increased from 14.8 to 
29.6 M, the percentage of apoptotic cells at 24 h incubation were 6.42% and 
16.36% respectively, showing a 2.5X increase in a dose-dependent manner.  
Interestingly, CNE2 cells exhibited a different cytotoxic response to quercetin 
compared to HK1.  At 14.8 M, quercetin was able to induce 11.14% of the cells 
to undergo apoptosis at 24 h.  However with prolonged exposure to quercetin at 
48 h incubation, a different cytotoxic effect was observed; at the same 
concentration of quercetin, 25.30% of CNE2 cells became necrotic and the 
percentage of apoptosis was decreased to almost basal level (as what was 
observed in control cells).   The necrotic effect of quercetin on CNE2 cells was 
also dose- as well as time- dependent as the percentage of necrotic cells increased 
with increased in quercetin concentration as observed in Fig 2.4I.  However, the 
increase in apoptotic cells with increase in quercetin concentration and time 
exposure was not observed.  Thus this study demonstrates that different 
nasopharyngeal carcinoma cell lines respond to quercetin in different manner.  At 
a lower concentration (14.8 M) of quercetin and 24 h incubation, both HK1 and 
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CNE2 cells were susceptible to quercetin and cell death by apoptosis was 
observed in both cell lines.  HK1 cells continued to exhibit susceptibility to 
quercetin and cell death by apoptosis was observed in a dose- and time-dependent 
manner.  However, when the concentration of quercetin was increased from 29.6 
M to 59.2 M, the percentage of apoptotic cells remained consistent at 24 h 
exposure (Fig 2.5I) but, the percentage of necrotic cells increased from 0.26% to 
14.46%.   In contrast, the cytotoxic response of CNE2 cells to quercetin was more 
necrotic and typically it followed a dose- and time-dependent manner.  At 24 h 
incubation, CNE2 cells was responsive to apoptosis brought about by quercetin 
but not in a dose-dependent manner as the percentage of apoptotic cells (10.13% 
to 14.28%)  did not vary much between 14.8, 29.6 and 59.2 M quercetin (Fig 
2.4I).  However, the percentage of necrosis became apparent in a dose- and time-
dependent manner; at 24 h, the percentage of necrosis increased from 4.33% to 
25.10% when quercetin concentration was increased from 14.8 M to 59.2 M.  
Moreover, at 14.8 M, the percentage of necrotic cells was 4.33% and 25.30% at 
24 and 48 h incubation respectively demonstrating a time-dependent response of 
CNE2 cells to the necrotic effect of quercetin.   
 Quercetin causes apoptosis in numerous cancer cells (Choi et al., 2001; 
Kang and Liang, 1997; Kobayashi et al., 2002; Salucci et al., 2002).  Separate 
studies by Choi et al (Choi et al., 2001) and Moon et al (Moon et al., 2003) have 
indicated that quercetin induced p21
CIP1
 expression but p53 level remained the 
same level, demonstrating that p21
CIP1
 may play an essential role in the induction 
of apoptosis in response to quercetin in a p53-independent pathway.  However, 
our experimental data together with those from Kobayashi et al (Kobayashi et al., 
2002) and Kaneuchi et al (Kaneuchi et al., 2003)  did not show a significant 




 expression when both cell lines, CNE2 and HK1 were treated 
with quercetin (Figs 2.3 A and B).  We therefore examined other mechanisms 
leading to apoptosis.  Mitochondria play a crucial role in the control of cell death 
as they provide major intracellular apoptotic signals in the form of cytochrome c 
(Huynh et al., 1995).  The release of cytochrome c and subsequent apoptosis can 
be regulated by the Bcl-2 family of proteins (Green and Reed, 1998; Moon et al., 
2003).  These proteins are divided into two groups; pro-apoptotic proteins such as 
Bad and Bax and anti-apoptotic proteins like Bcl-2 and Bcl-XL.  Bad and Bax 
proteins reside in the cytosol but translocate to the mitochondria following death 
signalling, where they promote the release of cytochrome c.  In our experiments, 
quercetin treatment on HK1 cells was able to up-regulate the expressions of Bad 
and Bax (Fig 2.6B).  However, when CNE2 cells were treated with quercetin, 
only Bad but not Bax expression was up-regulated (Fig 2.6B). 
 The release of cytochrome c into the cytosol of cell plays an important role 
in apoptosis through the activation of caspase proteins, amongst them caspase -3 
and -7 (Moon et al., 2003).  Our Western blot analyses (Figs 2.6 A and B) 
demonstrated that quercetin caused the cleavage of both caspase -3 and -7 to their 
respective active fragments in CNE2 as well as HK1 cells.  Once activated, active 
caspase-3 cleaves many substrate proteins downstream including PARP, resulting 
in DNA fragmentation and finally apoptosis.  Experimental results in Figs 2.6 A 
and B demonstrated that quercetin treated CNE2 and HK1 cells indeed exhibited 
an increased expression of the cleaved form of PARP.  Our findings suggest that 
in HK1 cells, quercetin induced apoptosis via the mitochondrial-initiated pathway 
through the recruitment of Bad and Bax proteins which would subsequently led to 
the activation of caspase proteins such as caspase -3 and -7; and  PARP.  For 
Page | 78  
 
CNE2 cells, apoptosis was induced via increased Bad but not Bax expression.  
Furthermore at a higher concentration of quercetin, cell death was mediated by 
necrosis. 
  






















Percentage of CNE2 undergoing 
Apoptosis (24 h) Necrosis (24h) Apoptosis (48h) Necrosis (48h) 
0 0.00 0.00 0.00 0.00 
14.8 11.14 4.33 0.65 25.30 
29.6 14.28 9.12 9.16 22.98 
59.2 10.13 25.10 1.80 25.92 
 
Fig 2.4: Annexin V-FITC/PI double staining flow cytometric analysis of 
CNE2 cells  
Actively dividing cells were incubated with quercetin in serum-free RPMI-1640 medium at 0, 
14.8, 29.6 and 59.2 M for 24 and 48 h, followed by flow cytometry analysis using Annexin V-
FITC/PI .  The data above were representative of experiments conducted in triplicates.  A - D, 
Cells were treated with 0, 14.8, 29.6 and 59.2 M for 24 h.  E – H, Cells were treated with 0, 14.8, 
29.6 and 59.2 M for 48 h.   I: All values for the cells in apoptosis and necrosis were computed 
against the control (0 M).  The lower right and upper right quadrants of each represent cells 
undergoing apoptosis.  The upper left quadrant represents cells undergoing necrosis. FL1-H: 








































Percentage of HK1 undergoing 
Apoptosis (24 h) Necrosis (24h) Apoptosis (48h) Necrosis (48h) 
0 0.00 0.00 0.00 0.00 
14.8 6.42 0.00 24.34 3.00 
29.6 16.36 0.26 24.77 12.12 
59.2 16.09 14.46 4.04 23.06 
 
 
Fig 2.5: Annexin V-FITC/PI double staining flow cytometric analysis of HK 
cells 
Actively dividing cells were incubated with quercetin in serum-free RPMI-1640 medium at 0, 
14.8, 29.6 and 59.2 M for 24 and 48 h, followed by flow cytometry analysis using Annexin V-
FITC/PI .  The data above were representative of experiments conducted in triplicates.  A - D, 
Cells were treated with 0, 14.8, 29.6 and 59.2 M for 24 h.  E – H, Cells were treated with 0, 14.8, 
29.6 and 59.2 M for 48 h.   I: All values for the cells in apoptosis and necrosis were computed 
against the control (0 M).  The lower right and upper right quadrants of each represent cells 
undergoing apoptosis.  The upper left quadrant represents cells undergoing necrosis.  FL1-H: 
Annexin V-FITC, FL2-H: PI. 
 
 




























Fig 2.6A: Quercetin mediates apoptosis via the intrinsic mitochondrial 
signalling pathway in CNE2 cells    
Cells were treated with different concentrations of quercetin for 24 and 48 h.  Total cellular protein 
extracts were prepared and subjected to immunoblotting.  Band intensity was quantified using the 
Bio-Rad Quantity-One programme and normalised against -tubulin.  The fold change/difference 









































Fig 2.6B: Quercetin mediates apoptosis via the intrinsic mitochondrial 
signalling pathway in HK1 cells  
Cells were treated with different concentrations of quercetin for 24 and 48 h.  Total cellular protein 
extracts were prepared and subjected to immunoblotting.  Band intensity was quantified using the 
Bio-Rad Quantity-One programme and normalised against -tubulin.  The fold change/difference 
was computed against the intensity of the band obtained from untreated cells at 24 h. 
 
 
2.4  Conclusions 
 
 In summary, our data presented in this report indicate that the flavonoid 
quercetin was able to induce cell growth inhibition in two nasopharyngeal 
carcinoma cell lines, CNE2 and HK1 through two different mechanisms; one by 
preventing cell cycle progression into the S phase through cell cycle arrest at the 
G2/M and G0/G1 phases.  The second mechanism is by inducing cell death and in 
the case of HK1 cells, mediated by apoptosis though a p53-independent 
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mitochondrial-initiated pathway.  Cell death is also observed in CNE2 cells and at 
low concentration of quercetin, cell death is also mediated by apoptosis.  At a 
higher concentration and with prolonged incubation, quercetin induces necrotic 
cell death in CNE2 cells.  It remains to be investigated how quercetin at higher 
concentration causes necrosis in CNE2 but not in HK1 cells. 
 Thus, our results together with findings from others, suggest that quercetin 
can be a potential agent for chemopreventive or therapy against nasopharyngeal 
carcinoma.  











































Luteolin induces G1 arrest in 
human nasopharyngeal 
carcinoma cells via the Akt-
GSK-3-cyclin D1 pathway 
Chapter 3 




 Flavonoids are polyphenolic compounds ubiquitously present in plants 
including fruits and vegetables.  There is growing evidence of the health benefits 
of flavonoids due to their biological activities such as anti-oxidant, anti-
inflammatory and anti-cancer (Middleton et al., 2000; Ross and Kasum, 2002).  
Among these activities, the anti-cancer effect of flavonoids has been extensively 
studied (Li et al., 2007; Lopez-Lazaro, 2002).  Many types of dietary flavonoids 
are able to inhibit cancer cell proliferation, induce cancer cell death by apoptosis 
and cell cycle arrest by targeting key intracellular molecules and pathways (Kale 
et al., 2008; Ramos, 2007).  For instance, the anti-proliferative activity of 
flavonoids on tumour cell growth has been linked to their effects on numerous 
intracellular biochemical pathways including the cyclins-cyclin-dependent kinases 
(CDKs) network (Singh and Agarwal, 2006). 
 Cyclins are essential components of the cell cycle machinery; each binds 
and activates specific types of cyclin-dependent kinases (CDKs).  Progression 
through the G1 phase of the cell cycle requires both cyclin D and cyclin E to 
activate CDK4/6 and CDK2 respectively (Obaya and Sedivy, 2002).  The cyclin 
D1-CDK4/6 complexes formed during G1 phase phosphorylate retinoblastoma 
(Rb) protein and activate the transcriptional factor E2F-1 which initiates the 
transcription of key cell cycle regulators such as cyclins E and A and in the 
process, driving cells into the S phase (Genovese et al., 2006; Giacinti and 
Giordano, 2006).  Therefore, it has been well established that cyclin D plays a 
crucial role in the progression of cell cycle from G1 to S phase and the down-
regulation of cyclin D will lead to cell cycle arrest at G1 (Blain, 2008; Malumbres 
and Barbacid, 2009). 
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 The phosphoinositide 3-kinase (PI3K)/Akt pathway is known to play a 
major role in cell cycle progression during the G1/S transition (Liang and 
Slingerland, 2003).  Amongst various substrates of Akt, several of them are 
involved in cell cycle regulation, including GSK-3, the forkhead transcription 




 (Blume-Jensen and Hunter, 2001).  
Akt is capable of phosphorylating GSK-3 at Ser9 and subsequently inhibiting its 
kinase activity.  Active GSK-3 phosphorylates cyclin D1 at Thr286 that triggers 
its subsequent ubiquitination and degradation by proteasomes (Diehl et al., 1998; 
Diehl et al., 1997).  Therefore, the Akt-GSK-3-cyclin D1 signalling pathway 
appears to be crucial in regulating the cell cycle at G1/S transition. 
 Luteolin (3’, 4’, 5’, 7’-tetrahydroxyflavone), a member of the flavonoid 
family which usually exists in the glycosylated forms, is commonly found in 
celery, green peppers, perilla leaf, camomile and chrysanthemum tea (Lopez-
Lazaro, 2009).  It exhibits a wide spectrum of pharmacologic properties ranging 
from anti-cancer, anti-oxidant, anti-inflammatory and anti-allergic properties (Lin 
et al., 2008; Seelinger et al., 2008a; Seelinger et al., 2008b).  At present, the anti-
cancer property of luteolin has been evaluated mainly on its ability to induce 
apoptosis (Lin et al., 2008).  For instance, luteolin is capable of directly inducing 
apoptotic cell death in numerous human cancer cells (Cheng et al., 2005; Fang et 
al., 2007b; Horinaka et al., 2005; Lee et al., 2005; Selvendiran et al., 2006; Xavier 
et al., 2009) and sensitising cancer cells to chemotherapeutics or biotherapeutic 
agents (Horinaka et al., 2005; Shi et al., 2007; Shi et al., 2004, 2005; Wu et al., 
2008).  However, relatively little is known about the anti-proliferative activity of 
luteolin.  Thus, in this study, we focussed on the effect of luteolin on cell cycle 
regulation.  Data from this study demonstrate that luteolin induces G1 arrest in 
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human nasopharyngeal carcinoma cells by down-regulating cyclin D1, which 
subsequently leads to suppression of the E2F-1 transcriptional activity.  We 
further identified the molecular mechanism in which luteolin down-regulates 
cyclin D1 through the inhibition of the Akt-GSK-3 signalling pathway.  Data 
from this study thus expand the spectrum of the anti-cancer potential of luteolin 
and support its potential application in cancer prevention and therapy 
 
3.2 Materials and methods 
 
3.2.1 Chemicals and reagents 
 Luteolin, insulin, lithium chloride (LiCl), DMSO, camptothecin, MG132 
as well as other chemicals were purchased from Sigma (St Louis, MO, USA).  
Cycloheximide (CHX), anti-cyclin D1 and anti-α-tubulin were purchased from 
Santa Cruz (Santa Cruz, CA, USA).  Anti-cyclin A, anti-cyclin E, anti-Rb, anti-
pRb Ser
780
, anti-Akt, anti-pAkt Ser
473
, anti-pcyclin D1 Thr
286
, anti-GSK-3β, anti-
pGSK-3β Ser9, anti-ubiquitin, horseradish peroxidase-conjugated goat anti-rabbit 
and goat anti-mouse secondary antibodies were purchased from Cell Signaling 
(Beverly, MA, USA).  Protease inhibitors cocktail was purchased from Roche 
(Mannheim, Germany).  RPMI-1640 and trypsin-EDTA (0.25% porcine trypsin 
and 0.02% EDTA-2Na) were purchased from Gibco Ltd (Grand Island NY, 
USA).  FBS was purchased from JRH Biosciences (Lenexa, KS, USA).  Reagents 
used for western blot analysis were purchased from Bio-Rad (Hercules, CA, 
USA).  The cell cycle-flow cytometry kit and apoptosis kit were from BD 
Biosciences (Palo Alto, CA, USA).  Enhanced chemiluminescent substrate was 
purchased from Pierce (Rockford, USA).  The ubiquitinated protein enrichment 
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kit was purchased from Calbiochem (San Diego, USA).  RT-PCR experiment was 
conducted using the Qiagen Onestep RT-PCR kit (Qiagen, Valencia, USA).  
Lipofectamine 2000 transfection reagent was purchased from Invitrogen Life 
Technologies (Carlsbad, CA, USA). 
 
3.2.2 Cell culture and treatment 
Nasopharyngeal carcinoma cell lines HK1 and CNE2 were kindly 
provided by Dr. KM Hui, Singapore, National Cancer Centre.   Cells were grown 
and maintained at 37
o
C in a humidified 5% CO2 and 95% air atmosphere in 
RPMI-1640 supplemented with 10% FBS.  Equal number of cells were seeded in 
RPMI-1640 supplemented with 10% FBS.  In order to synchronise cell cycle, the 
medium was switched to FBS-free overnight before treatment with luteolin in 
RPMI-1640 supplemented with 10% FBS.  As luteolin was dissolved in DMSO, 
the same concentration of DMSO was always applied to the control group.  For 
the pre-treatment experiments, cells were pre-treated with 1.0 μM MG132, 200 
nM insulin or 30 mM LiCl for one h before luteolin treatment.  For pre-treatment 
with CHX, cells were pre-treated with 0.5 μg/ml of CHX for 30 mins. 
 
3.2.3 Cell cycle analysis 
 Cell cycle analysis by flow cytometry was performed using the 
bromodeoxyuridine – 7-amino-actinomycin D (BrdU-7-AAD) kit.  Briefly, treated 
and control cells were first labelled with BrdU (final concentration of 1 mM) in 
culture for 15 mins and subsequently harvested.  These cells were subjected to a 
second round of labelling with FITC-conjugated antibody to BrdU and 7-AAD as 
described by the instruction manual.  This was followed by flow cytometry 
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analysis.  With this combination of BrdU and 7-AAD, a two-colour flow 
cytometric analysis permits the enumeration and characterisation of cells in terms 
of their cell cycle position including G0/G1, S and G2/M phases.      
 
3.2.4 Apoptosis analysis 
 Flow cytometry to detect and quantify the presence of apoptotic cells was 
first conducted using an active caspase-3-FITC antibody apoptosis kit (BD 
Biosciences).  Cells were harvested and permeabilised using saponin buffer 
followed by incubation with anti-active caspase-3-FITC conjugated monoclonal 
antibodies.  Apoptotic cells were detected and quantified by flow cytometry. 
 
3.2.5 Immunoblot analysis 
 Cells were first lysed in cell lysis (20 mM Tris, pH 7.5, 150 mM NaCl, 
1mM PMSF, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM 
EDTA, 1mM EGTA, 1% Triton-X100, 1mM sodium vanadate, 1mM PMSF 
(Phenylmethanesulfonylfluoride) and a protease inhibitor cocktail).  Equal amount 
of proteins were fractionated on SDS-PAGE gel using the Mini-PROTEAN II 
system (Bio-Rad) before being transferred to nitrocellulose membrane (Bio-Rad).  
The membrane was first blocked with 5% fat-free milk in TBST (10 mm Tris-
HCl, pH 7.5, 100 mM NaCl and 0.1% Tween-20), followed by probing with the 
various primary antibodies and developed using the enhanced chemiluminescent 
reagents (Pierce).  Detection of specific bands could be viewed using the Kodak 
Image Station 4000MM Pro.    
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3.2.6 Immunoprecipitation of ubiquitinated enriched proteins 
 Cells were lysed in lysis buffer (50 mM HEPES, pH 7.5, 5 mM EDTA, 
150 mM NaCl, 1% Triton®  X-100 , 10 mM N-ethylmaleimide and a protease 
inhibitor cocktail). Cell extracts were added to polyubiquitin affinity beads 
(Calbiochem) and incubated at 4
o
C for 2 – 4 h with constant mixing to allow the 
binding of ubiquitinated proteins to beads.  Ubiquitinated bound proteins were 
subsequently detached from the beads by boiling in the presence of SDS gel 
loading buffer, separated by SDS PAGE and blotted onto nitrocellulose 
membrane for detection of both cyclin D1 and ubiquitin. 
 
3.2.7 RT-PCR 
mRNA was extracted using the Qiagen Onestep RT-PCR kit and RT-PCR 
performed using the following primers (Qi et al., 2007) .  Forward and reverse 
primer sequences for cyclin D1 were 5TAG CAG CAA ACA ATG TGA AAG 
AG3 and 5CTT ACA TCA TAG CAA CAC GGA CTT3 respectively.  Forward 
and reverse primer sequences for cyclin E were 5AGA AGC CAA CCA CAG 
TCT ATA CCA3 and 5TTA CGA CAC CGA GGA AGG ATT GA3 
respectively.  Forward and reverse primer sequences for β-actin were 5CCA 
AGG CCA ACC GCG AGA AGA TGA C3 and 5CAG ACC GCC GTG GTG 
GTA CAT GGG A3 respectively. 
 
3.2.8 Luciferase reporter gene assay 
 The transient transfection of E2F-1 luciferase vector (Promega, Madison, 
WI, USA) was performed in HK1 cells using Lipofectamine 2000 transfection 
reagent (Invitrogen Life Technologies) according to the manufacturer’s protocols. 
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Renilla luciferase vector, which acts as a transfection control, was also 
cotransfected.  Luciferase activity was measured in the cellular extracts using a 
Dual-Luciferase Reporter Assay System (Promega) based on the protocol 
provided by the manufacturer. Briefly, following the treatments, cell lysate was 
collected from each well of the 24-well plate after the addition of cell lysis 
reagent.  After the addition of the luciferase assay substrate, firefly luciferase 




3.3.1 Luteolin induces cell cycle arrest at G1 phase in a dose- and time- 
dependent manner 
 
 The effects of luteolin on the cell cycle progression in two NPC lines, HK1 
and CNE2 were determined by flow cytometry with anti-BrdU-FITC and 7-AAD 
staining.  In HK1 cells, treatment with various concentrations of luteolin for 24 h 
resulted in a dose-dependent increase in the percentage of cells in G0/G1 phase 
and a concomitant reduction of cell numbers in S phase (Fig 3.1A, upper panel).  
Higher concentrations of luteolin (50 and 100 M) almost completely abolished 
the S phase in these cells (Fig 3.1A, lower panel).  CNE2 also exhibited a similar 
pattern when treated with luteolin: it underwent G1 arrest in a dose-dependent 
manner (Fig 3.1B).  Consistent with the occurrence of G1 cell cycle arrest, there 
was a dose-dependent reduction in total number of HK1cells counted per well 
with 24 h of luteolin treatment (Fig 3.1C, lower panel).  This was further verified 
by microscopic examination that showed a decrease of viable cell number in 
treated samples (Fig 3.1C, upper panel). 
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 Using HK1 cells for subsequent studies, we next investigated the temporal 
pattern of G1 arrest induced by 50 M luteolin.  An increase of G0/G1 cells was 
observed from 3 h onwards, with concomitant reduction of cells in S phase (Fig 
3.1D) in a time-dependent manner.  Taken together, these data indicate that 
luteolin arrests cell cycle progression at G1 in both HK1 and CNE2 in a dose- and 
time- dependent manner. 
  


























Fig 3.1 A & B: Luteolin induces cell cycle arrest at G1 in a dose- and time- 
dependent manner in HK1 and CNE2 cells 
(A) HK1 cells were first synchronised by maintaining the cells in FBS-free medium overnight 
before treatment with luteolin in RPMI-1640 supplemented with 10% FBS for 24 h and labelled 
with BrdU for 15 mins.  Cells were subsequently harvested and stained with anti-BrdU-FITC and 
7-AAD and subjected to flow cytometry assay as described under Section 3.2.  The percentage of 
cells in G0/G1, S and G2/M phases based on BrdU incorporation (anti-BrdU-FITC) (FL1) and 7-
AAD staining on DNA (FL3) was quantified by manual gating of the dot plots.  Values are 
presented as means  SD from three independent experiments.  (B) A similar experiment as that in 
(A) was performed on CNE2 cells.  Cells were treated with designated concentrations of luteolin 
for 24 h.  
 
 












































Fig 3.1C & D: Luteolin induces cell cycle arrest at G1 in a dose- and time- 
dependent manner in HK1 and CNE2 cells 
HK1 cells were treated as in (A), harvested, stained with trypan blue and counted using a 
haemocytometer.  Values are presented as means  SD from three independent experiments (lower 
panel).  Micrographs of luteolin treated and untreated cells (100X) (upper panel).  (D) HK1 was 
treated with 50 M luteolin for the indicated period using experiment procedure to (A) and cell 
analysis by flow cytometry conducted for the percentage of cells in G1and S phases.  All numeric 
data are presented as means  SD from three independent experiments. 
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3.3.2 Luteolin does not induce apoptosis in HK1 and CNE2 cells 
 
 Luteolin has been found to induce apoptosis in a number of studies (Lin et 
al., 2008). In our study, we also determined whether luteolin was capable of 
inducing apoptosis in both HK1 and CNE2 cells.  Apoptotic cell death was 
quantified using the active caspase-3 apoptotic kit coupled with flow cytometry.  
Interestingly, there was no apoptotic cell death in HK1 treated with luteolin when 
treated for 24 h (Fig 3.2 A – D), while treatment with 20 M camptothecin 
induced significant increase of caspase-3 activation (Fig 3.2E).  No caspase-3 
activation was found even when treatment for up to 48 h (Fig 3.2 F – I).  Similar 
negative results were also obtained with other apoptotic markers such as PARP 
cleavage as determined by Western blot.  Luteolin was also unable to cause 
apoptosis in CNE2 when treated for up to 48 h, similar to the effect in HK1 cells 
(Fig 3.3).  Since earlier work in our laboratory has demonstrated luteolin-induced 
apoptosis in other human cancers (Shi et al., 2007; Shi et al., 2004, 2005), it is 
























































Fig 3.2: Luteolin fails to induce apoptosis in HK1 cells   
Cells were treated with luteolin for 24 h with designated concentrations.  Cells treated with 20 M 
camptothecin for 24 were used as a positive control.  Cells were harvested and stained with 
antibody to active caspase-3-FITC, followed by analysis with flow cytometry.  Gates were 
configured manually to measure the percentage of apoptotic cells (M2) versus non-apoptotic cells 
(M1).  Presented histograms were representatives from three independent experiments. 
 





Fig 3.3: Luteolin fails to induce apoptosis in CNE2 cells 
Cells were treated with luteolin for 24 h with designated concentrations.  Cells were harvested and 
stained with antibody to active caspase-3-FITC, followed by analysis with flow cytometry.  Gates 
were configured manually to measure the percentage of apoptotic cells (M2) versus non-apoptotic 
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3.3.3 Luteolin induces cell cycle arrest at G1 phase by down-regulation 
of cyclin D1 and subsequent suppression of E2F-1 transcription 
activity 
 
 In order to understand the molecular mechanisms underlying the G1 cell 
cycle arrest in HK1 cells induced by luteolin, we examined the level of cyclin D1, 
the main cyclin controlling the G1/S checkpoint (Obaya and Sedivy, 2002).  It 
was found that luteolin treatment led to rapid reduction of cyclin D1 protein level 
(Fig 3.4A).  It is well established that cyclin D1 is required for CDK4/6 to 
phosphorylate Rb and subsequent release of the transcriptional factor E2F-1 to 
initiate cell cycle progression to S phase (Genovese et al., 2006; Giacinti and 
Giordano, 2006).  Here, we also observed a significant reduction of Rb 
phosphorylation level (Fig 3.4A), indicating the compromised activation of the 
CDK4/6.  Consistently, the protein levels of cyclin A and E, the two main 
transcriptional targets of E2F-1 were also decreased (Fig 3.4A).  We further 
measured the mRNA level of cyclin E using RT-PCR and it was evident that 
luteolin treatment resulted in suppression of cyclin E gene transcription (Fig 
3.4B).  To further confirm that luteolin inhibits the transcriptional activity of E2F-
1, we utilised the E2F-1 luciferase reporter vector and the results in Fig 3.4C 

















































Fig 3.4: Luteolin down-regulates cyclin D1 and suppresses Rb 
phosphorylation and E2F-1 transcription activity in HK1 cells   
(A) Cells were treated with 50 M luteolin for the indicated periods.  Total cellular protein 
extracts were prepared and subjected to immunoblotting.  (B) Detection of cyclin E mRNA level 
using RT-PCR, as described in Section 3.2.  -actin was used as an internal control.  (C) Changes 
of E2F-1 transcription activity.  Cells were first transfected with the E2F-1 luciferase construct 
together with the Renilla vector using Lipofectamine 2000.  Transfected cells were subsequently 
treated with luteolin and their luciferase activity measured using a Dual-Luciferase Reporter Assay 
System (Promega).  Values are presented as means  SD from three experiments. 
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3.3.4 Luteolin promotes phosphorylation and subsequent proteasomal 
degradation of cyclin D1 
 
 After establishing the critical role of cyclin D1 and its downstream events 
in luteolin-induced cell cycle arrest, here we sought to investigate the underlying 
molecular mechanism leading to cyclin D1 down-regulation in luteolin-treated 
HK1 cells.  To address whether the reduction of cyclin D1 protein level was due 
to the suppression of gene expression, we first checked the mRNA level of cyclin 
D1 using RT-PCR.  As shown in Fig 3.5A, the cyclin D1 mRNA level remained 
unchanged when cells were treated with luteolin for 3 h, suggesting that luteolin 
could down-regulate cyclin D1 via translational and post-translational regulations. 
 We next examined whether luteolin affects the protein stability of cyclin 
D1 using CHX to inhibit de novo protein synthesis.  As shown in Fig 3.5B, in the 
presence of CHX, luteolin led to further reduction of cyclin D1 protein level, 
indicating that luteolin is likely to down-regulate cyclin D1 protein level via 
promotion of protein degradation. 
 We next tested the two important post-translational modifications of cyclin 
D1: phosphorylation and ubiquitination.  As shown in Fig 3.5C, in the presence of 
MG132, a specific proteasome inhibitor, treatment with luteolin significantly 
enhanced the phosphorylation of cyclin D1.  The low level of phosphorylated 
cyclin D1 in the control group (without MG132) is most probably due to the rapid 
degradation of the phosphorylated protein.  Consistently, MG132 prevented the 
reduction of cyclin D1 protein level in cells treated with luteolin (Fig 3.5C).  
Moreover, in order to test the effect of luteolin on ubiquitination of cyclin D1, we 
performed immunoprecipitation (IP) using polyubiquitin affinity beads to pull 
down the ubiquitinated protein.  As shown in Fig 3.5D (upper panel), treatment 
with luteolin enhanced the level of ubiquitinated proteins, especially in the 
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presence of MG132.  Consistently, luteolin markedly promoted ubiquitination of 
cyclin D1 in the presence of MG132 (middle panel).  The total cyclin D1 protein 
level was also detected in the whole lysate (lower panel), with similar findings as 
shown earlier in Fig 3.5C.  One intriguing finding from both Figs 3.5 B and D is 
that the basal level of cyclin D1 was not increased in the presence of MG132 
whereas the phospho-cyclin D1 level enhanced markedly.  One possible 
explanation is that the basal phosphorylation of cyclin D1 does not trigger 
significant proteasomal degradation.  Taken together, these data indicate that 
luteolin-induced down-regulation of cyclin D1 is mediated by enhanced protein 
phosphorylation, ubiquitination and subsequent proteasomal degradation. 
  





































Fig 3.5 A – C: Luteolin enhances cyclin D1 ubiquitination and proteasomal 
degradation in HK1 cells 
(A) Detection of cyclin D1 mRNA level using RT-PCR in HK1 cells after treatment with luteolin 
for 3 h.  -actin was used as an internal control.  (B) Cyclin D1 protein stability assay.  Cells were 
pre-treated with 0.5 g/ml CHX for 30 mins, followed by luteolin treatment for 1 h.  Total cellular 
protein extracts were prepared and subjected to immunoblotting.  (C) Detection of phospho-cyclin 
D1.  Cells were pre-treated with 1.0 M MG132 for 1 h followed by luteolin treatment.  Total 
cellular protein extracts were prepared and subjected to immunoblotting.  -Tubulin was used as a 
loading control.  
 












































Fig 3.5D: Luteolin enhances cyclin D1 ubiquitination and proteasomal 
degradation in HK1 cells 
(D) Detection of cyclin D1ubiquitination.  Cell lysates from cells treated using the same 
experimental condition as in (C) was used for immunoprecipitation using polyubiquitin affinity 
beads, as described in Section 3.2, followed by immunoblotting with anti-ubiquitin and anti-cyclin 




Page | 104  
 
3.3.5 Luteolin inhibits the Akt-GSK-3 signalling pathway upstream of 
cyclin D1 
 
 It has been established that cyclin D1 phosphorylation is mediated by the 
Akt-GSK-3 pathway (Diehl et al., 1998; Diehl et al., 1997).  Activated Akt 
phosphorylates and inhibits GSK-3 function, leading to the de-phosphorylation 
and stabilisation of cyclin D1.  We therefore examined whether the Akt-GSK-3-
cyclin D1 axis was involved in luteolin-induced degradation of cyclin D1 in HK1.  
In our experiment, we first found that luteolin rapidly and markedly suppressed 
Akt phosphorylation, as early as 15 mins (Fig 3.6).  Consistent with the inhibition 
of Akt activity, phosphorylation of GSK-3, a target of Akt kinase, was also 
reduced (Fig 3.6), suggesting that luteolin likely promotes cyclin D1 











Fig 3.6: Luteolin suppresses Akt and GSK-3 phosphorylation in HK1 cells  
Cells were treated with luteolin for the indicated periods.  Total cellular protein extracts were 
prepared for immunoblotting to detect the levels of phospho-Akt Ser
473,
 total Akt, phosphor-GSK-
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 To further examine the involvement of Akt-GSK-3 signalling pathway, 
we pre-treated HK1 cells with LiCl, an inhibitor of GSK-3 before luteolin 
treatment.  As shown in Fig 3.7A, pre-treatment with LiCl could reverse the effect 
of luteolin on GSK-3 phosphorylation and when HK1 cells were treated with 
insulin, insulin could nullify the inactivation of Akt and subsequent activation of 
GSK-3 in luteolin-treated cells (Fig 3.7A).  As a result, both insulin and LiCl 
were capable of reducing the phosphorylation of cyclin D1 (Fig 3.7B), and 
subsequently the down-regulation of cyclin D1 protein level induced by luteolin 
(Fig 3.7B).  In order to detect the presence of the phosphorylated form of cyclin 
D1 as this protein is rapidly in cells, cells must first be pre-treated with MG132 as 
illustrated in Fig 3.7B.  Finally, we verified the effect of insulin on the cell cycle 
profile in luteolin-treated cells.  As shown in Fig 7C, pre-treatment with insulin 
significantly increased the percentage of cells in S phase in HK1 cells treated with 
luteolin.  Similar results were also obtained when the experiment was repeated 
using CNE2 cells (Fig 3.7D).  Taken together, these findings suggest that luteolin 
suppresses the Akt-GSK-3 pathway, leading to enhanced cyclin D1 


































Fig 3.7 A – C: Insulin and LiCl prevent down-regulation of cyclin D1 induced 
by luteolin in HK1 cells 
(A) HK1 cells were pre-treated with either 200 nM insulin or 30 mM LiCl, followed by 50 M 
luteolin treatment for 3 h.  Total cellular protein extracts were prepared for immunoblotting.  -
Tubulin was used as a loading control.  (B) HK1 cells were treated using the same experimental 
condition as (A) and in the presence of MG132.  Total cellular protein extracts were prepared for 
immunoblotting.  -Tubulin was used as a loading control.  (C) HK1 cells were first synchronised 
in FBS-free medium overnight before pre-treatment with 200 nM insulin followed by 50 M 
luteolin treatment for 3 h.  BrdU was added 15 mins before the end of incubation.  Cells were 
subsequently harvested and stained with anti-BrdU-FITC and 7-AAD, followed by flow cytometry 
analysis to quantify the percentage of cells in G0/G1 and S phase, as described in Fig 3.1A.   Data 
in C are presented as means  SD from three independent experiments. 
 

















Fig 3.7D:  Insulin and LiCl abrogate the effects of luteolin on CNE2 cells 
Cells were first synchronised in FBS-free medium overnight before pre-treatment with 200 nM 
insulin followed by 40 M luteolin treatment for 3 h.  BrdU was added 15 mins before the end of 
incubation.  Cells were subsequently harvested and stained with anti-BrdU-FITC and 7-AAD.  





 At present, the anti-cancer potential of luteolin is mainly based on its 
ability to induce apoptosis in cancer cells (Lin et al., 2008).  However, relatively 
little is known about the effect of luteolin on cell cycle progression.  Several 
earlier reports have found that luteolin induces cell cycle arrest either at G1 by 
down-regulating cellular protein levels of cdk4 and cdk6 (Casagrande and 
Darbon, 2001; Lim do et al., 2007) or G2/M arrest by the inhibition of cdc2 and 
up-regulation of p21
CIP1
 (Wu et al., 2008).  In the present study, we identified the 
molecular mechanism in luteolin-induced G1 arrest: luteolin inhibits the Akt-
GSK-3-cyclin D1 signalling pathway, promotes cyclin D1 phosphorylation and 
proteasomal degradation, and subsequently causing hypophosphorylation of Rb 
and suppression of the E2F-1 transcriptional activity. 
 Progression from G1 to S phase of the cell cycle is controlled by cyclin Ds 
and their kinases, namely cdk4 and cdk6, which act by phosphorylating and 
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inactivating Rb, thus liberating E2F-1 transcriptional activity to drive the cells 
into S phase (Genovese et al., 2006; Malumbres and Barbacid, 2009).  In this 
study, we first defined the critical role of cyclin D1 in luteolin-induced cell cycle 
arrest.  It is well known that cyclin D1 is important in the development and 
progression of numerous cancers (Gladden and Diehl, 2005; Tashiro et al., 2007).  
Moreover, cyclin D1 over-expression is a common event in cancer and is usually 
a result of defective regulation at the post-translational level (Kim and Diehl, 
2009).  Therefore, regulation of cyclin D1 protein level is one of the critical 
aspects in cell proliferation and tumour development.  An earlier study by Diehl et 
al (Diehl et al., 1997) demonstrated that cyclin D1 degradation is dependent on 
Thr
286 
phosphorylation by GSK-3 and ubiquitin-dependent proteasomal 
degradation.  Interestingly, we found that luteolin acts on this signalling pathway 
in HK1 cells, resulting in the induction of cell cycle arrest.  An increase in the 
phospho form of cyclin D1 Thr
286
 was observed but due to the rapid turnover of 
this protein, it could only be detected when cells were pre-treated with MG132 
before luteolin treatment (Fig 3.5C).  As GSK-3 regulates cyclin D1 degradation, 
a GSK-3-specific inhibitor LiCl was able to suppress luteolin-induced down-
regulation of this protein (Fig 3.7B), suggesting the involvement of the GSK-3 
pathway in luteolin-mediated cell cycle arrest. 
 Frequent activation of Akt has been reported in many human cancers 
(Altomare and Testa, 2005; Tokunaga et al., 2008) and GSK-3 has been 
identified as one of Akt’s molecular targets.  Akt inactivates GSK-3 kinase 
activity by site-specific phosphorylation at Ser
9 
which leads to subsequent 
reduction in cyclin D1 phosphorylation and an increase in its protein stability 
(Diehl, 2002).  In this study, we found that luteolin is capable of inhibiting Akt 
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phosphorylation and activation.  It remains to be investigated how luteolin inhibits 
Akt enzymatic activity.  One possibility is that luteolin may target 
phosphoinositide 3-kinase (PI3K), as suggested by earlier reports (Bagli et al., 
2004; Lee et al., 2006). 
 It has been extensively studied that luteolin induces apoptotic cell death in 
many cancer cells (Lin et al., 2008).  Interestingly, in our study, luteolin was 
unable to induce apoptosis in HK1 and CNE2 cells, as verified by the absence of 
active caspase-3 in luteolin-treated cells by flow cytometry (Figs 3.2 and 3.3) and 
cleaved PARP proteins by Western blot (data not shown).  Since these cells are 
capable of undergoing apoptosis as demonstrated by camptothecin treatment (Fig 
3.2), the exact reason for the lack of apoptotic response to luteolin in HK1 and 
CNE2 cells is not clear.  One possible explanation is that this group of NPC cells 
exhibit a high basal level of Akt activation (as shown in Fig 3.7A), thus making 
them more susceptible to the inhibitory effect of luteolin on cell cycle via the Akt-
GSK-3-cyclin D1 pathway.  It would be of interest to elucidate the underlying 
mechanisms responsible for the different response to luteolin by different types of 
cancer cells. 
 NPC is one of the common cancers in the regions of East Asia, especially 
among the Chinese (Chan et al., 2003; Hanley et al., 1995; Yu, 1991).  The main 
modalities for NPC are chemotherapy and radiotherapy.  Our study demonstrates 
that luteolin is able to suppress NPC cell proliferation via cell cycle arrest by 
targeting the Akt-GSK-3-cyclin D1 signalling axis.  Since Akt is often over-
activated in many human cancers including NPC (Chou et al., 2008; Tokunaga et 
al., 2008), it is thus believed data from this study support the potential application 
of luteolin as a chemotherapeutic or chemopreventive agent in human cancer. 


























Luteolin and quercetin 
sensitise NPC cells to the 








 The traditional treatment for NPC includes radiation and chemotherapy.   
There are two major limitations with these conventional therapies: resistance and 
toxic side-effects (Chua et al., 2005; Ngan et al., 2002; Wong et al., 2006). Many 
tumours exhibit a good response when they are first exposed to chemotherapeutic 
drugs, however the majority of patients eventually develop resistance to these 
agents.  Therefore, acquired resistance to chemotherapy is a major obstacle to 
successful cancer treatment.  Understanding the molecular mechanisms in which 
tumours become resistant to a particular therapeutic is thus critical.   
 Several mechanisms of drug resistance have been identified, including (i) 
changes to membrane transporters that result in reduced drug accumulation, (ii) an 
enhanced DNA damage repair mechanism; and (iii) multiple deficiencies in 
apoptosis induction in tumour (Abrams et al., 2010; Goto and Takano, 2009; 
Pauwels et al., 2007; Zhou et al., 2008).  In addition, alteration to critical 
signalling pathways such as the PI3K/Akt pathway has also been associated with 
drug resistance (Huang and Hung, 2009; Li et al., 2010a; Liang et al., 2009).  
PI3K/Akt pathway is known to play a central role in many cellular physiological 
functions and in numerous cancers this pathway is up-regulated (reviewed in 
Section 1.2 of this thesis).  This has generated an increasing interest in designing 
drugs that specifically target the PI3K/Akt pathway as single agent or in 
combination to other chemotherapeutic agents to overcome drug resistance. 
 Quercetin, a flavonoid has been identified to possess inhibitory activity 
against the PI3K/Akt pathway (Matter et al., 1992).  Subsequently, more specific 
and potent inhibitors like wortmannin (Arcaro and Wymann, 1993) and 
LY294002 (Vlahos et al., 1994) were developed.  However, the use of these 
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inhibitors as potential candidates in tumour growth inhibition was dampened by 
the fact that it is impractical to use as in vivo pharmacological agents due to their 
toxicity and insolubility.  This leads to the hunt for other novel agents to 
overcome chemoresistance (Ihle and Powis, 2009).  Identified inhibitory agents 
work on different aspects of the PI3K/Akt pathway.  These include inhibitors that 
(i) inhibit catalytic activity of PI3K via its PH domain-PtdIns(3,4,5)P3 interaction 
for example inositol pentakisphosphate (Piccolo et al., 2004), (ii) interfere with 
Akt translocation to the plasma membrane like perifosine (Kondapaka et al., 
2003) and (iii) inhibit Akt activation like phosphatidylinositol ether lipid 
analogues and GSK690693 (Gills et al., 2006; Rhodes et al., 2008). 
 Microtubules are components of the cytoskeleton with important roles in 
intracellular trafficking of vesicles and organelles, maintenance of cell shape and 
polarity; cellular motility; cell signalling and mitotic chromosome segregation 
(Nogales, 2001).  During mitosis, microtubules form the mitotic spindle separate 
daughter chromosomes to the two poles of a dividing cell.  Any agents that 
interfere with microtubule dynamics will inhibit the ability of cells to successfully 
complete mitosis, thus making the microtubules a desirable target for the 
development of chemotherapeutics against rapidly dividing cancer cells. 
Microtubule inhibitors like taxanes (De Dosso and Berthold, 2008; Nishiyama and 
Wada, 2009; Rodriguez-Antona, 2010), vinca alkaloids (Chan and Verrill, 2009; 
Eden et al., 2010; Lin et al., 2010) and epothilones (Frye, 2010; Hurtig, 2010; 
Larkin and Kaye, 2006) alone or in combinations with other chemotherapeutics 
have been used against many solid and haematologic malignancies.  Taxanes and 
epothilones interact with polymerised tubulin and prevent depolymerisation, while 
vinca alkaloids bind to monomeric tubulin and prevent polymerisation.  The 
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success of microtubule inhibitors as cancer therapeutics has been plagued with the 
development of acquired drug resistance in tumour cells (Fojo and Menefee, 
2007; McGrogan et al., 2008).  One strategy to overcome this drug resistance is to 
use a multiple drug treatment approach.   Each agent in the multiple drug regime 
is administered at sub-cytotoxic dose (less toxic side-effect and lower the chance 
of developing drug resistance) and yet able to achieve the same efficacy at a 
higher dosage as each agent works on targeting a different site, thus leading to an 
overall additive or synergistic cytotoxic effects on tumours.  There are reports 
where microtubule inhibitors like docetaxel (Gomez et al., 2006; Motwani et al., 
2003) and epothilone B (Wittmann et al., 2003) when combined with flavonoids 
like flavopiridol (semi-synthetic flavonoid) were able to improve the overall 
efficacy of treatment on cancer cells like prostate cancer, breast cancer and gastric 
cancer compared to the single agents.   
  In Chapter 3 of this thesis, we have identified luteolin, a natural plant 
flavonoid that is able to inhibit Akt very efficiently by preventing Akt 
phosphorylation at ser
473
.  In the first part of this study, a panel of conventional 
chemotherapeutics used for NPC treatment in patients was selected.  This includes 
5-Fluorouracil (5-FU) (Azli et al., 1992), docetaxel (DTX) (Ngeow et al., 2010), 
paclitaxel (PTX) (Chan et al., 2004) and vincristine (VCR) (Kwong et al., 2004) 
used singly or in combination with sub-cytotoxic dose of luteolin or quercetin 
were screened to identify paired combinations that were able induced cell death 
(microscopic examination of cell death) in two nasopharyngeal carcinoma cell 
lines, HK1 and CNE2.  DTX, PTX and VCR are mitotic inhibitors that affect 
microtubule formation during cell division.  5-FU is an anti-metabolite that 
inhibits thymidylate synthase and thus prevents the synthesis of thymidine.  In the 
Page | 114  
 
second part of the study, the identified combinations of either luteolin or quercetin 
and chemotherapeutics were used on the same cell lines and cell death by 
apoptosis determined by flow cytometry.  The data obtained clearly demonstrate 
that luteolin and quercetin were able to sensitise HK1 and CNE2 cells to VCR-
induced cell death when VCR was used at sub-cytotoxic concentration.  Cell 
death was mediated by caspase-3-dependent apoptosis. 
 




4.2.1 Chemicals and reagents 
 
 Luteolin, quercetin, DMSO, VCR, 5-FU, docetaxel, paclitaxel as well as 
other chemicals were purchased from Sigma (St Louis, MO, USA).  zVAD-fmk 
was purchased from Enzo Life Sciences (Plymouth Meeting, PA, USA).  Anti-α-
tubulin was purchased from Santa Cruz (Santa Cruz, CA, USA).  Anti-Akt, anti-
pAkt Ser
473
, anti-caspase-3, anti-PARP, horseradish peroxidase-conjugated goat 
anti-rabbit and goat anti-mouse secondary antibodies were purchased from Cell 
Signaling (Beverly, MA, USA).  Protease inhibitors cocktail was purchased from 
Roche (Mannheim, Germany).  RPMI-1640 and trypsin-EDTA (0.25% porcine 
trypsin and 0.02% EDTA-2Na were purchased from Gibco Ltd (Grand Island NY, 
USA).  FBS was purchased from JRH Biosciences (Lenexa, KS, USA).  Reagents 
used for Western blot analysis were purchased from Bio-Rad (Hercules, CA, 
USA).  The active caspase-3 apoptosis kit was purchased from BD Biosciences 
(Palo Alto, CA, USA).  Enhanced chemiluminescent substrate was purchased 
from Pierce (Rockford, USA).    
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4.2.2 Cell culture and treatment 
 Nasopharyngeal carcinoma cell lines HK1 and CNE2 were used in this 
study.   Cells were grown and maintained at 37
o
C in a humidified 5% CO2 and 
95% air atmosphere in RPMI-1640 supplemented with 10% FBS.  Equal number 
of cells were seeded in RPMI-1640 supplemented with 10% FBS.  As luteolin, 
quercetin and all test chemotherapeutics were dissolved in DMSO, the same 
concentration of DMSO was always applied to the control group.  All treatments 
on cells were conducted in RPMI-1640 supplemented with 1% FBS. 
 
4.2.3 Apoptosis analysis 
 Flow cytometry to detect and quantify the presence of apoptotic cells was 
performed using an active caspase-3-FITC antibody apoptosis kit (BD 
Biosciences).  Cells were harvested and permeabilised using saponin buffer 
followed by incubation with anti-active caspase-3-FITC conjugated monoclonal 
antibodies.  Apoptotic cells were detected and quantified by flow cytometry (This 
method used is similar to the one used in Chapter 3 of this thesis). 
 
4.2.4 Immunoblot analysis 
 Cells were first lysed in cell lysis buffer (20 mM Tris, pH 7.5, 150 mM 
NaCl, 1mM PMSF, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 
mM EDTA, 1mM EGTA, 1% Triton-X100, 1mM sodium vanadate, 1mM PMSF 
(Phenylmethanesulfonylfluoride) and a protease inhibitor cocktail).  Equal amount 
of proteins were fractionated on SDS-PAGE gel using the Mini-PROTEAN II 
system (Bio-Rad) before being transferred to nitrocellulose membrane (Bio-Rad).  
The membrane was first blocked with 5% fat-free milk in TBST (10 mm Tris-
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HCl, pH 7.5, 100 mM NaCl and 0.1% Tween-20), followed by probing with the 
various primary antibodies and developed using the enhanced chemiluminescent 
reagents (Pierce).  Detection of specific bands could be viewed using the Kodak 
Image Station 4000MM Pro.    
 
4.2.5 Statistical analysis 
 The apoptotic effects of flavonoids and vincristine singly and in 
combination on cells as quantified by flow cytometry (active caspase-3) were 
analysed using the statistical analysis software from Statgraphics® Centurion 




4.3.1 Luteolin sensitises CNE2 cells to the cytotoxic effect of VCR 
 
 In this study, sub-cytotoxic concentration of luteolin at 10 M was 
selected.  A total of four chemotherapeutics namely 5-fluorouracil (5-FU), 
docetaxel (DTX), vincristine (VCR) and paclitaxel (PTX) was used singly or in 
combination with 10 M luteolin in CNE2 cells for 24 h or 48 h.  Experiments 
were performed in which these cells were first pre-treated with 10 M luteolin in 
RPMI-1640 supplemented with 1% FBS  for two hours, followed by the addition 
of various concentrations of chemotherapeutics for the remaining 24 h.   These 
cells were subsequently observed under the microscope for morphological 
changes (Fig 4.1).  Based on morphological examination of cells treated for 24 h, 
it was observed that 5-FU alone and in combination with luteolin did not lead to 
cell death of CNE2 cells (Fig 4.1A).  Luteolin in combination with DTX, VCR or 
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PTX was able to augment cell death in CNE2 cells (Fig 4.1 B – D).   With the 
exception of 5-FU, DTX, VCR and PTX were used in nanomolar range (Fig 4.1). 
 The cytotoxic effect of luteolin plus VCR was observed to be time 
dependent as with prolonged incubation to 48 h, cell death was more apparent 
compared to 24 h (Fig 4.1C and Fig 4.2).   
  
  









































Fig 4.1: Combined effect of luteolin (Lu) and chemotherapeutics on CNE2 
cells 
Cells were first grown overnight in full medium (RPMI-1640 supplemented with 10% FBS) and 
pre-treated with 10 M Lu for 2 h before the addition of chemotherapeutics for 24 h.  Cells were 
treated in RPMI-1640 supplemented with 1% FBS. Micrographs of cells were captured at total 
magnification of 100X.   (A) 5-Fluorouracil (5-FU) at 0 to 10 M.  (B) Docetaxel (DTX) at 0 to 5 






D: PTX  
 
C: VCR 













Fig 4.2: Combined effect of 10 M luteolin (Lu) and 2 nM VCR on CNE2 
cells for 48 h 
Cells were first grown overnight in full medium (RPMI-1640 supplemented with 10% FBS) and 
pre-treated with 10 M Lu for 2 h before the addition of 2 nM VCR for up to 48 h.  Cells were 
treated in RPMI-1640 supplemented with 1% FBS. Micrographs of cells were captured at total 
magnification of 100X.  
 
 
 As morphological study indicated that sub-cytotoxic combination of 
luteolin and VCR together was able to induce cell death in CNE2 cells, we next 
performed flow cytometry to quantify the cytotoxic effect of this combination.    
 It was observed that the percentage of apoptotic cells in CNE2 cells after 
luteolin, 1 or 2 nM VCR- treated were 3.77%, 4.17% and 5.25% respectively with 
untreated cells exhibiting a base level of apoptosis at 2.12% (Fig 4.3) after 48 h of 
treatment.  These values of apoptosis after these treatments were considered 
negligible when compared to untreated cells, thus indicating that luteolin and 
VCR alone could not induce apoptotic cell death in these cells.  However, when 
luteolin was combined with 1 or 2 nM VCR, the percentage of cell death by 
apoptosis rose to 17.23 and 22.70% respectively (Fig 4.3).  Based on these 
percentages, one could observe that luteolin sensitised CNE2 cells to the cytotoxic 
effect of VCR that resulted in a caspase-3-dependent apoptotic cell death. 
  
 




















Fig 4.3: Quantification of the combined cytotoxic effect of Lu and VCR on 
CNE2 cells 
Cells were pre-treated with 10 M Lu for 2 h before the addition of VCR up to 48 h.  They were 
subsequently harvested and stained with antibody to active caspase-3-FITC, followed by flow 
cytometry analysis to quantify the percentage of apoptotic cells as described in Materials and 
Methods).   (A) Histogram plots of the results obtained from the flow cytometry experiments.   In 
the upper panel, the results were obtained from cells treated with VCR alone.  Results in the lower 
panel were obtained when cells were treated with Lu and VCR. Gates were configured manually to 
measure the percentage of apoptotic cells (M2) versus non-apoptotic cells (M1).  (B) The 
percentage of apoptotic cells (M2) is presented as means  SD from three independent 
experiments and represented by bar chart.  Data are presented as means  SD from three 
independent experiments and represented by bar chart.  *: Data compared to the control group 
(DMSO, Lu or VCR alone) based on One-way ANOVA with Scheffe’s test exhibits a statistically 
significant difference. 
A: CNE2 cells 
B: CNE2 cells 
 
4 nM VCR 2 nM VCR 1 nM VCR DMSO 
    
+ 10 M Lu 
Control 
 
DMSO 1 nM VCR 
 
2 nM VCR 
 
4 nM VCR 
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4.3.2 Luteolin sensitises HK1 cells to the cytotoxic effect of VCR 
 
 
 We next performed preliminary screening using 5-FU, DTX and VCR 
together with luteolin on HK1 cells.   Luteolin did not sensitise these cells to the 
growth inhibitory effect of 5-FU and DTX (data not shown).   Like CNE2, HK1 
cells could be sensitised by luteolin to the cytotoxic effect of VCR and in a time-
dependent manner since there was visually more cell death at 48 h compared to 
the same treatment for 24 h (Fig 4.4).   The concentration of VCR used was also 
similar to that for CNE2 treatment, which was 1, 2 and 4 nM. 
 The percentage of cell death mediated by the combined luteolin and VCR 
treatment on HK1 cells for 48 h was quantified by flow cytometry.  A value 
equivalent to 6.53%, 2.43% and 5.23% of apoptotic cell death was observed in 
HK1 cells treated with 10 M luteolin, 1 nM VCR and 2 nM VCR respectively, 
with the base level of apoptosis observed in untreated cells at 3.29% (Fig 4.5).  
When these cells were treated with luteolin in combination with either 1 or 2 nM 
VCR, the percentage of cell death by apoptosis increased to 28.17% and 31.93% 
respectively (Fig 4.5).  These data demonstrated that the combined treatment of 
luteolin and VCR on HK1 cells was able to augment a cytotoxic effect resulting in 
cell death.  Based on the percentage of cell death, it was observed that luteolin 
exerted the same effect on HK1cells as observed in CNE2 cells; it sensitised HK1 
cells to VCR, resulting in a caspase-3-dependent apoptotic cell death. 
 
  


























Fig 4.4: Combined effect of 10 M luteolin (Lu) and 2 nM VCR on HK1 cells 
for (A) 24 h and (B) 48 h   
Cells were first grown overnight in full medium (RPMI-1640 supplemented with 10% FBS) and 
pre-treated with 10 M Lu for 2 h before the addition of 2 nM VCR for up to 24 or 48 h.  Cells 
were treated in RPMI-1640 supplemented with 1% FBS. Micrographs of cells were captured at 
total magnification of 100X.  
 
  
   
  
A: 24 h (HK1 cells) 
 
B: 48 h (HK1 cells) 
 


































Fig 4.5: Quantification of the combined cytotoxic effect of Lu and VCR on 
HK1 cells 
Cells were pre-treated with 10 M Lu for 2 h before the addition of VCR up to 48 h.  Cells were 
treated in RPMI-1640 supplemented with 1% FBS.   They were subsequently harvested and 
stained with antibody to active caspase-3-FITC, followed by flow cytometry analysis to quantify 
the percentage of apoptotic cells.  (A) Histogram plots of the results obtained from the flow 
cytometry experiments. In the upper panel, the results were obtained from cells treated with VCR 
alone.  Results in the lower panel were obtained when cells were treated with Lu and VCR.  Gates 
were configured manually to measure the percentage of apoptotic cells (M2) versus non-apoptotic 
cells (M1).  (B) The percentage of apoptotic cells (M2) is presented as means  SD from three 
independent experiments and represented by bar chart.  Data are presented as means  SD from 
three independent experiments and represented by bar chart.  *: Data compared to the control 
group (DMSO, Lu or VCR alone) based on One-way ANOVA with Scheffe’s test exhibits a 
statistically significant difference. 
A: HK1 cells 
B: HK1 cells 
 
4 nM VCR 2 nM VCR 1 nM VCR DMSO 
    
+ 10 M Lu 
Control 
4 nM VCR 
 
DMSO 1 nM VCR 
   
2 nM VCR 
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4.3.3 zVAD-fmk abrogates the cytotoxic effects of luteolin and VCR on 
CNE2 and HK1 cells 
 
 To verify whether the cytotoxic effect of luteolin and VCR on CNE2 was 
due to an increase in active caspase-3 expression, cells were pre-treated with 
luteolin and or 40 M zVAD-fmk, a pan-caspase inhibitor for 2 h before being 
treated with VCR at 2 nM up to 48 h before the cells were subjected to flow 
cytometry.  Luteolin sensitised CNE2 cells to 2 nM VCR resulting in cell death 
equivalent to 27.30% (Fig 4.6A).  The presence of zVAD-fmk completely blocked 
cell death induced by luteolin and VCR as verified by reduction of apoptotic cell 
death equivalent to 2.70% (basal level of apoptosis observed in control cells was 
2.57%).   
 The same experiments were also performed on HK1 cells.  As the data in 
Fig 4.6B indicated, zVAD-fmk was able to abrogate luteolin and VCR induced 
cell death from 35.90% to 3.20%.   
 Based on these results, it seems that augmentation of cell death by the 
combined treatment of luteolin and VCR on CNE2 and HK1 cells was mediated 
by a caspase-3-dependent apoptotic cell death since zVAD-fmk could abrogate 
the cytotoxic effect.    
  
  


































Fig 4.6: Cytotoxic effect of Lu and VCR on CNE2 (A), and HK1 (B) cells 
could be abrogated by zVAD-fmk  
Cells were first grown overnight in full medium (RPMI-1640 supplemented with 10% FBS) and 
pre-treated with 10 M Lu and/ or 40 M zVAD-fmk for 2 h before the addition of VCR for  48 h.  
Cells were treated in RPMI-1640 supplemented with 1% FBS.   Cells were harvested and stained 
with antibody to active caspase-3-FITC, followed by flow cytometry analysis to quantify the 
percentage of apoptotic cells.  Data are presented as means  SD from three independent 
experiments. *: Data compared to the control group (DMSO, Lu or VCR alone) based on One-way 
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4.3.4 Quercetin sensitises HK1 cells to the cytotoxic effect of VCR and 
this effect can be abrogated by zVAD-fmk 
 
 We next examined the cytotoxic effect of quercetin and VCR on HK1.  
Quercetin at 5 M was used in these experiments as this concentration did not 
cause cell death (based on morphological examination of cells). This 
concentration was subsequently used together with 2 nM VCR where cells were 
incubated for 48 h with both reagents.  Quercetin, like luteolin could sensitise 
HK1 cells to 2 nM VCR, resulting in cell death (Fig 4.7).  This cytotoxic effect 
was also time-dependent as more cell death was visually observed in the 48 h 









Fig 4.7: Combined effect of 5 M quercetin (Qu) and 2 nM VCR on HK1 
cells for 48 h 
Cells were first grown overnight in full medium (RPMI-1640 supplemented with 10% FBS) and 
pre-treated with5 M for 2 h before the addition of 2 nM VCR for the remaining 48 h.  Cells were 
treated in RPMI-1640 supplemented with 1% FBS. Micrographs of cells were captured at total 
magnification of 100X.  
 
 Cell death was further quantified by flow cytometry.  In this experiment, 
cells were treated like in previous experiment with luteolin and VCR.  
Experimental data illustrated that VCR alone was unable to induce cell death by 
apoptosis (percentage of apoptotic cells of VCR and DMSO treated cells was 
4.43% and 2.30% respectively).  HK1 cells were more susceptible to quercetin 
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compared to luteolin as at 5 M quercetin, there was 12.20% apoptotic cell death 
compared to 6.53% in 10 M luteolin treated sample.  When HK1 cells were 
treated with both quercetin and VCR, the percentage of apoptotic cell death 
increased to 37.03% which was considered to be statistically significant compared 
to the control and single agents when these data were analysed by One-way 
ANOVA with Scheffe’s test (Fig 4.8).  Like in luteolin treated HK1 cells, 
quercetin was able to sensitise the cells to the cytotoxic effect of VCR.  As 
illustrated in Fig 4.8, cell death was mediated by the caspase-3-dependent 
pathway since zVAD-fmk could block cell death (the percentage of apoptotic cell 
death in sample pre-treated with zVAD-fmk and luteolin followed by VCR was 
4.13% with basal level of apoptosis in the control sample at 2.30%). 
  
















Fig 4.8: Cytotoxic effect of Qu and VCR on HK1 cells could be abrogated by 
zVAD-fmk 
Cells were first grown overnight in full medium (RPMI-1640 supplemented with 10% FBS) and 
pre-treated with 5 M Qu and/ or 40 M zVAD-fmk for 2 h before the addition of VCR for  48 h.  
Cells were treated in RPMI-1640 supplemented with 1% FBS.  Cells were harvested and stained 
with antibody to active caspase-3-FITC, followed by flow cytometry analysis to quantify the 
percentage of apoptotic cells.  The percentage of apoptotic cells is presented as means  SD from 
three independent experiments. . *: Data compared to the control group based on One-way 




4.3.5 Sensitisation effect of flavonoids on VCR-induced cell death is 
mediated by caspase-3-dependent apoptosis 
 
 To verify that the sensitisation of cells by luteolin or quercetin to the 
cytotoxic effect of VCR is mediated by a caspase-3-dependent apoptotic pathway, 
western blot experiments were performed to detect for the presence of proteins 
like active caspase-3 and PARP.  CNE2 and HK1 cells were pre-treated with 10 
M luteolin and/or 40 M zVAD-fmk for 2 h before the addition of 2 nM VCR 
for 48 h.  Cellular extracts were subsequently obtained from these treated cells 
and used for western blot experiments.  Similarly HK1 cells were also pre-treated 
with 5 M quercetin and/or 40 M zVAD-fmk before the addition of 2 nM VCR 
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for 48 h.  Cellular extracts of these treated cells were also obtained and used for 
western blot experiments.     
 Luteolin and VCR alone did not induce apoptosis in CNE2 and HK1 cells 
as no cleavage of caspase-3 and PARP was observed (Fig 4.9 A and B).   
However, cleaved caspase-3 and PARP proteins were observed in cellular extracts 
from luteolin and VCR as well as quercetin and VCR treated cells (Fig 4.9 A and 
B).    
 In the previous flow cytometry experiment, 5 M quercetin induced 
12.20% of apoptosis in HK1 cells (Fig 4.8) and this could be verified by western 
blot experiment where there was  slight increase in active caspase-3 (Fig 4.9C). 
However the intensity of the cleaved caspase-3 in sample obtained from quercetin 
and VCR treated HK1 cells was more apparent (Fig 4.9C).  PARP cleavage 
followed closely the pattern of cleaved caspase-3.    
  









































Fig 4.9: The combined effects of either Lu or Qu with VCR led to an increase 
in cleaved and active caspase-3 and PARP in CNE2 and HK1 cells 
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4.4 Discussion 
 There are numerous ways to limit cancer cell growth; one of which is 
chemotherapy: the use of chemical agents which interferes with the rapid division 
of cells.  The untargeted nature of the chemotherapeutics inevitably causes toxic 
side effects on healthy cells especially those that divide quickly.  In recent years, 
the necessity for more effective treatment with reduced toxic side effects has led 
to the development of targeted therapy where the anti-cancer agent interferes with 
macromolecules in cancer cells.  Such targeted therapy has resulted in a dramatic 
improvement in cancer treatments.  However problems continue to persist.  One 
of the major setbacks is the development of drug resistance despite the fact that 
many tumours show an initial good response when they are first exposed to these 
chemotherapeutics but patients eventually developed resistance to these agents.   
 Several mechanisms of drug resistance have been identified which include 
membrane transporters that lead to a decrease in drug accumulation, enhanced 
DNA damage repair mechanism and multiple deficiencies in the activation of 
apoptosis (Pauwels et al., 2007; Zhou et al., 2008).  In addition, alteration to 
critical signalling pathways such as the PI3K/Akt pathway has also been 
associated with drug resistance (Huang and Hung, 2009; Li et al., 2010a).  
PI3K/Akt pathway is known to play central role in many cellular physiological 
functions and in many cancers, this pathway is up-regulated. There are also 
reports that reveal its key role in drug resistance (Huang and Hung, 2009; Li et al., 
2010a; Liang et al., 2009).  Therefore there is an increasing interest in designing 
drugs that specifically target this pathway as single agent or in combination to 
other chemotherapeutic agents to overcome drug resistance. 
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 In this study, we demonstrated that flavonoids like luteolin and quercetin 
sensitised Akt-expressing cells like nasopharyngeal carcinoma cell lines, HK1 and 
CNE2 to VCR-induced apoptosis.  Our results showed that pre-treatment of HK1 
and CNE2 cells with luteolin or quercetin, followed by sub-cytotoxic 
concentration of VCR was able to induce a significant increase in apoptosis and 
growth inhibition compared with cells treated with each agent alone.  The 
sensitisation effect by the flavonoid was associated with the activation of caspase-
3 which could be abrogated with zVAD-fmk, pan-caspase inhibitor.  Hence, the 
combination of flavonoids like luteolin and quercetin with VCR could potentially 
be useful in cancer therapy of the nasopharynx.  However this study does not 
answer queries on the molecular interaction of these two chemicals inside cells.  
Therefore the challenge ahead is to understand the underlying mechanism leading 
to the augmentation of cell death brought about by flavonoids like luteolin or 
quercetin together with VCR.   
  






























General Discussion and 
Conclusions 
Chapter 5 
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5.1 Quercetin-induced growth inhibition and cell death in 
nasopharyngeal carcinoma cells are associated with increase in Bad 
and hypophosphorylated retinoblastoma expressions 
 
 Nasopharyngeal carcinoma (NPC), a head and neck cancer of epithelial 
origin has a high incidence rate in Southern China and South-East Asia with an 
incidence rates of between 15 and 50 per 100 000 in man (Ho, 1978).  In 
Singapore, the incidence rates are 18.4 per 100 000 in males and 7.3 per 100 000 
in females (Chia et al., 1996).  NPC is responsive to radiotherapy for which there 
is a high local control rate after radical radiotherapy (RT) (Fang et al., 2007a; Lu 
and Yao, 2008).  Studies have illustrated that concurrent radiotherapy and 
chemotherapy (chemoradiotherapy) results in a statistically significant reduction 
in failure and cancer-specific deaths compared with radiotherapy alone (Lee et al., 
2010a).   Chemotherapeutics used in chemoradiotherapy include cisplatin, 5-
fluorouracil, vincristine, bleomycin and methotrexate (Airoldi et al., 2010; Kwong 
et al., 2004; Lin et al., 2003).  However, toxicities were observed in some patients 
after chemotherapy which led to mucositis (Wong et al., 2006), grade III/IV 
neutropenia (Chua et al., 2004; McCarthy et al., 2002) , grade III/IV anaemia, 
granulocytopenia thrombocytopenia (Leong et al., 2005; Ngan et al., 2002).  The 
potential use of natural products like flavonoids may circumvent some of these 
toxicities experienced by patients.   
 Quercetin (3, 3, 4, 5, 7-pentahydroxylflavone) is a flavonol-type 
flavonoid ubiquitously present in plant-derived foods and is the most abundant 
amongst the flavonoid family.  It is found in a variety of fruits like red onion, 
grapes, apples, berries, cherries, broccoli, citrus fruits and tea.  Many biological 
effects of quercetin on cells and tissues have been reported (reviewed by 
(Bischoff, 2008).  Of interest in this report is its anti-cancer property.  There are 
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numerous studies that demonstrate the effects of quercetin on signal transductions 
associated with tumourigenesis and these include cell cycle regulation, apoptosis, 
pro-inflammatory protein induction and angiogenesis (Hirpara et al., 2009; 
Murakami et al., 2008).   
 In this study (experimental details and data are presented in Chapter 2 of 
this thesis), we demonstrate that quercetin was able to induce cell growth 
inhibition in two nasopharyngeal carcinoma cell lines, CNE2 and HK1 through 
two different mechanisms; one by preventing cell cycle progression into the S 
phase through cell cycle arrest at the G2/M and G0/G1 phases.  This was 
mediated by the inhibition of E2F-1 function via complex formation with the 
hypophosphorylated form of Rb (Fig 2.3).  The second mechanism is the 
induction of cell death by apoptosis via a p53-independent mitochondrial-initiated 
pathway.  This was mediated by the presence of  pro-apoptotic proteins like Bad 
and Bax in quercetin treated cells which led to subsequent activation of caspase -7 
and -3 (Fig 2.6).  Another interesting finding is that at a higher concentration and 
with prolonged incubation quercetin induces necrotic cell death in CNE2 but not 
in HK1 cells (Fig 2.4 and 2.5).  It remains to be investigated how quercetin at 
higher concentration causes necrosis in CNE2 but not in HK1 cells. 
 In conclusion, this study (Chapter 2 of this thesis) demonstrates that 
quercetin is able to arrest cell growth by preventing quercetin treated CNE2 and 
HK1 cells to progress to the S phase.  At low concentration, it is able to induce 
apoptosis and at higher concentration, necrosis ensued.  The molecular 
mechanism that results in the cell cycle arrest and apoptosis by quercetin is 
mediated by the inactivation of E2F-1 by Rb and the increase in the presence of 
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pro-apoptotic proteins like Bad and Bax which leads to the cleavage and 
activation of caspase -3 and -7.   
 
5.2 Luteolin induces G1 arrest in human nasopharyngeal carcinoma 
cells via the Akt-GSK-3-cyclin D1 pathway 
  
 Luteolin (3, 4, 5, 7- tetrahydroxylflavone) is a flavonol-type flavonoid 
ubiquitously present in plant-derived foods.  Luteolin-rich vegetables and fruits 
include celery, parsley, broccoli, onion leaves, carrots, peppers, cabbages, apple 
skins and chrysanthemum flowers (Miean and Mohamed, 2001; Sun et al., 2007; 
Xie et al., 2009). 
 Luteolin exhibits a wide range of biological activities in the prevention and 
treatment of chronic diseases due to their anti-oxidant, anti-inflammatory, anti-
microbial and anti-cancer activities (reviewed by (Lopez-Lazaro, 2009).  In our 
laboratory, luteolin has been found to enhance TNF--induced apoptosis in 
human colorectal cancer COLO205, HCT116 and cervical cancer Hela cells via 
suppression of NF-B (Shi et al., 2004).  In a second study, pre-treatment of 
TRAIL-sensitive cancer cells like Hela and TRAIL-resistant cancer cells like 
CNE1, HT29 and Hep G2 with a non-cytotoxic concentration of luteolin was able 
to enhance TRAIL-induced apoptosis mediated by caspase -8 and -3 activation 
(Shi et al., 2005).   
 At present, the anti-cancer potential of luteolin is mainly based on its 
ability to induce apoptosis in cancer cells (Lin et al., 2008).  However, relatively 
little is known about the effects of luteolin on cell cycle regulation.  Several 
earlier reports have demonstrated that luteolin induces cell cycle arrest either at 
G1 by down-regulating cellular protein levels of CDK4 and CDK2 (Casagrande 
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and Darbon, 2001; Lim do et al., 2007) or G2/M arrest by the inhibition of cdc2 
and up-regulation of p21
CIP1
 (Wu et al., 2008). 
 In this study, we also focussed on the effect of luteolin on cell cycle 
regulation in human nasopharyngeal carcinoma cells.  We identified a different 
molecular mechanism leading to cell cycle arrest by luteolin.  Luteolin inhibits the 
Akt-GSK-3-cyclin D1 signalling pathway in the NPC line, HK1 by promoting 
cyclin D1 phosphorylation and subsequent proteasomal degradation.  In the 
absence of cyclin D1, pRb is maintained in the hypophosphorylated form and this 
prevents the activation of E2F-1 transcription activity.   
 Progression from G1 to S phase of the cell cycle is controlled by cyclin Ds 
and their kinases, namely CDK4 and CDK6, which act by phosphorylating and 
inactivating Rb, thus liberating E2F-1 transcriptional activity to drive the cells 
into S phase (Genovese et al., 2006; Malumbres and Barbacid, 2009).  In this 
study, we first defined the critical role of cyclin D1 in luteolin-induced cell cycle 
arrest.  It is well known that cyclin D1 is important in the development of 
numerous cancers including NPC (Gladden and Diehl, 2005; Tashiro et al., 2007; 
Xie et al., 2000) (reviewed in Chapter 1.3 of this thesis).  Moreover, cyclin D1 
over-expression is a common event in cancer and is usually a result of defective 
regulation at the post-translational level (Kim and Diehl, 2009).  Therefore, 
regulation of the cyclin D1 protein level is one of the critical aspects in cell 
proliferation and tumour development.  An earlier study by Diehl et al (Diehl et 
al., 1997) demonstrated that cyclin D1 degradation is dependent on Thr
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phosphorylation by GSK-3 and ubiquitin-dependent proteasomal degradation.  
Interestingly, we found that luteolin acts on this signalling pathway in HK1, 
resulting in the induction of cell cycle arrest.  An increase in the phospho form of 




 was observed when HK1 was treated with luteolin.  As GSK-3 
regulates cyclin D1 degradation, a GSK-3-specific inhibitor, LiCl, suppressed 
luteolin-induced down-regulation of this protein, suggesting the involvement of 
the GSK-3 pathway in luteolin-mediated cell cycle arrest. 
 Frequent activation of Akt has been reported in many human cancers 
(Altomare and Testa, 2005; Tokunaga et al., 2008)  and GSK-3 has been 
identified as one of Akt’s molecular targets.  Akt inactivates GSK-3 kinase 
activity by site-specific phosphorylation at Ser
9
 which leads to subsequent 
reduction in cyclin D1 phosphorylation and an increase in its protein stability 
(Diehl, 2002).  In this study, we found that luteolin is capable of inhibiting Akt 
phosphorylation and activation.  It remains to be investigated how luteolin may 
target PI3K, as suggested by earlier reports (Bagli et al., 2004; Lee et al., 2006). 
 Interestingly in our study luteolin was unable to induce apoptosis in HK1 
and CNE2 (although these cells are responsive to camptothecin-induced 
apoptosis) when many studies have demonstrated the apoptotic effects of luteolin 
on numerous cancer cell lines.  The exact reason for this lack of apoptotic 
response to luteolin by HK1 and CNE2 is not clear.  One possible explanation is 
that this group of cells have higher basal level of Akt activation (as demonstrated 
in Chapter 3 of this thesis), thus making them more susceptible to the inhibitory 
effect by luteolin on cell cycle via the Akt-GSK-3-cyclin D1 pathway.  It would 
be of interest to elucidate the underlying mechanisms responsible of the different 
response by different types of cancer cells. 
 Thus, this study (Chapter 3 of this thesis) demonstrates that luteolin is able 
to suppress NPC cells proliferation via cell cycle arrest by targeting the Akt-GSK-
3-cyclin D1 signalling axis.  Since Akt is often over-activated in many human 
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cancers including NPC, it is thus believed that the data from this study support the 
potential application of luteolin as a chemotherapeutic or chemopreventive agent 
in human cancer. 
 
5.3 Luteolin and quercetin sensitise NPC cells to the cytotoxic effect of 
chemotherapeutics 
 
 The traditional treatment for NPC includes radiotherapy or chemotherapy 
or a combination of both (chemoradiotherapy).  Concurrent chemotherapy 
together with radiotherapy is able to reduce failure and cancer-specific deaths 
when compared with radiotherapy alone in patients (Lee et al., 2010a).  However, 
cumulative incidence of acute toxicity increases with chemotherapy as observed 
in numerous studies (Lee et al., 2010a; Lu et al., 2009).  Moreover many patients 
eventually develop resistance to anti-cancer agents.  Thus, acquired resistance to 
chemotherapy is another major hurdle to successful cancer treatment.  
Understanding the underlying mechanisms in which tumours become resistance to 
particular therapeutics is therefore critical.    
 Several mechanisms of drug resistance have been associated with major 
signal transduction pathways including the PI3K/Akt pathway (Li et al., 2010a; 
Liang et al., 2009).  There is now an increasing interest in designing drugs that 
specifically target this pathway as single agent or in combination with other 
chemotherapeutics to overcome drug resistance. 
 In this study, we combined the effects of VCR, a chemotherapeutic that 
affect microtubule dynamics in cells with flavonoids like luteolin and quercetin 
which can inhibit the PI3K/Akt pathway.  Both agents were added to cells at sub-
cytotoxic concentrations.  
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 Microscopic examination illustrated that the combined treatment of 
flavonoid (either luteolin or quercetin) and vincristine led to cell death but not for 
cells treated with either flavonoid or vincristine alone.  The percentage of cell 
death by caspase-3-dependent apoptosis was quantified by flow cytometry and 
verified by western blot experiments that detected apoptotic markers like active 
caspase-3 and PARP.  The presence of zVAD-fmk, a pan-caspase inhibitor was 
able to abrogate the combined cytotoxic effect of flavonoid and vincristine on 
both cell lines.   
 The data obtained from this study was also analysed based on analysis 
variance by One-way ANOVA using the statistical analysis software from 
Statgraphics® Centurion XVI.  Results indicated that luteolin and quercetin were 
able to sensitise HK1 and CNE2 cells to VCR, resulting in apoptotic cell death, 
whereas the individual reagents were unable to kill the cells.      
 This preliminary study however, does not answer queries on how the two 
chemicals interact with each other to enhance cell death by apoptosis.  It will be 
interesting to elucidate the underlying cell signalling pathways leading to the 
sensitisation of NPC cells to vincristine induced by luteolin and quercetin which 
subsequently resulted in the augmentation of cell death in these cells. 
 
5.4 Future studies 
 It has been estimated that 75 – 85% of all chronic illness and diseases are 
associated with lifestyle and cannot be explained by differences in genetic 
makeup alone (Wong et al., 2005).  A review of 206 human epidemiological 
studies and 22 animal studies conducted by Steinmetz & Potter demonstrated an 
inverse relationship between consumption of fruits and vegetables; and the risk of 
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developing cancers of the stomach, oesophagus, lung, oral cavity, pharynx, 
endometrium, pancreas and colon (Steinmetz and Potter, 1996). 
 While fruits and vegetables are recommended for the prevention of cancer 
as well as other diseases, the active components and their underlying mechanisms 
leading to cancer cell growth and inhibition are not well understood.  Although 
extensive research over the past decades has identified various molecular targets 
that these bio-active reagents can potentially inhibit and prevent cancer, however 
lack of success with targeted monotherapy using these agents has redirected 
researchers to employ either combination therapy or agents that interfere with 
multiple cell signalling pathways.  Aggarwal and Shishodia have presented a 
review identifying known bio-active agents in fruits and vegetables and their 
effects on several cell signalling pathways (Aggarwal and Shishodia, 2006).  Such 
agents include curcumin, genistein, lycopene, capsaicin, diosgenin, luteolin, 
quercetin, catechins and beta carotene to name a few.  Major cell signalling 
pathways affected by these bio-active agents include the NK-B, AP-1, STAT3, 
Akt, Bcl-2, Bcl-XL, caspases, PARP, IKK, EGFR, HER2, JNK, MAPK and 
COX2 (reviewed by (Aggarwal and Shishodia, 2006).   
 To translate the successful and meaningful data obtained from studies 
performed in in vitro cell culture systems and animal models to human with 
beneficial pharmacological effects, several challenges and obstacles need to be 
overcome.  One most immediate challenge will be the ability to deliver and 
accumulate concentration of bio-active agents in tissues and organs high enough 
to achieve chemopreventive effect.  Most preclinical mechanistic studies on 
dietary bio-active agents performed in cell lines and animal models may have 
adopted significantly higher doses than the amounts that are consumed in our 
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daily diet.  Unlike therapeutics like tamoxifen used for breast cancer prevention, 
dietary chemopreventive bio-active agents might not possess the optimum 
pharmacokinetics and toxicology profiles.  Due to their natural chemical 
properties some of them may have poor absorption in the gut upon oral ingestion, 
extensive metabolic breakdown leading to rapid clearance from the body which 
render them unavailable or make them available in a pharmacologically inactive 
form.  If ever a high blood concentration of the bio-active agent is achieved, 
cytotoxicity to normal cells may be observed.  To overcome some of these 
inherent problems associated with bio-active agents, potential agents can be 
chemically modified to make them less resistant to metabolism, more stable in the 
blood and therefore can reach target tissues at a concentration that is toxic to 
cancer cells but not to the normal cells. 
 Another practical strategy is to explore the use of bio-active agents 
together with current therapeutics whereby a cytotoxic synergism can be reached 
to augment cell death with lower concentrations of both chemicals and yet achieve 
the same efficacy in vivo when patients are exposed to a higher but toxic 
concentration of the individual agents.  In our study, we have reported a 
preliminary but promising result in which flavonoids like luteolin and quercetin 
are able to sensitise NPC cells to sub-cytotoxic concentration of VCR and yet 
achieve cell death.  However to bring this work to fruition with the ultimate aim 
of using the combination of flavonoids with other therapeutics, it will require 
more work to be done to truly understand and map the molecular targets of 
luteolin and quercetin which ultimately results in cell death, establishing animal 
models to verify the efficacy of these treatments in vivo  and at the same time, 
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study the various mechanism to deliver these bio-active agents to target sites at 
concentration high enough to bring about cytotoxic effect on cancer cells.   
 
5.5 Conclusions 
 In this study, we have systemically investigated the anti-cancer property of 
flavonoids like quercetin and luteolin on human nasopharyngeal carcinoma cells 
and we have: 
1. identified the mechanism leading to quercetin-mediated cell cycle arrest in 
S phase was due to the inhibition of E2F-1 activity.  In addition, quercetin 
induced apoptosis through Bad and Bax. 
2. demonstrated that luteolin inhibited cell cycle progression at G1 phase was 
via the Akt-GSK-3-cyclin D1 pathway, which resulted in enhanced 
protein phosphorylation of cyclin D1 and subsequent proteasomal 
degradation of this protein.  Luteolin, however was unable to induce 
apoptosis in NPC cells. 
3. illustrated the sensitisation effect of luteolin and quercetin on apoptosis 
induced by vincristine. 
 
 Our findings provide evidence to support the potential application of 
quercetin and luteolin as chemopreventive and chemotherapeutic chemicals or 
when used in combination with other chemotherapeutics as chemosensitiser in 
cancer treatment and management. 
One must also be cautioned that data obtained from in vitro cell culture 
system do not translate into successful results in an in vivo environment.  Thus in 
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vivo studies using animal models will be required to verify the potential 
applications of these flavonoids in cancer prevention and management. 
In conclusion, this work reaffirms what Hippocrates said 2500 years ago, I 
quote “Let food by thy medicine and medicine be thy food’ unquote. 
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